{"DataElement":{"publicId":"6677723","version":"1","preferredName":"Off-Treatment Chemotherapy Administered Chemotherapy Regimen Type","preferredDefinition":"The indicated off treatment chemotherapy received","longName":"OFFTX_CHX_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2195138","version":"1","preferredName":"Off-Treatment Chemotherapy Administered","preferredDefinition":"information related to the off-treatment chemotherapy being administered.","longName":"OTX_CT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206851","version":"1","preferredName":"Off-Treatment Chemotherapy","preferredDefinition":"Off-Treatment; the phase of a protocol during which a patient does not receive treatment.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C25601:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Off Treatment","conceptCode":"C25601","definition":"When a patient is not receiving therapy they are considered off treatment.  In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0B3C-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED0521FD-58D3-144A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018959","version":"3","preferredName":"Chemotherapy Regimen Type","preferredDefinition":"the type of chemotherapy regimen received by the patient.","longName":"CT_RGM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"3 month anthracycline based","valueDescription":"3 MONTH ANTHRACYCLINE BASED","ValueMeaning":{"publicId":"2565981","version":"1","preferredName":"3 MONTH ANTHRACYCLINE BASED","longName":"2565981","preferredDefinition":"3 MONTH ANTHRACYCLINE BASED","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA670A9-0FB8-0537-E034-0003BA12F5E7","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"6 month/cycle anthracycline based","valueDescription":"6 MONTH/CYCLE ANTHRACYCLINE BASED","ValueMeaning":{"publicId":"2565982","version":"1","preferredName":"6 MONTH/CYCLE ANTHRACYCLINE BASED","longName":"2565982","preferredDefinition":"6 MONTH/CYCLE ANTHRACYCLINE BASED","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CECB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA670A9-0FBA-0537-E034-0003BA12F5E7","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"6 month/cycle non-anthracycline regimen","valueDescription":"6 MONTH/CYCLE NON-ANTHRACYCLINE REGIMEN","ValueMeaning":{"publicId":"2565983","version":"1","preferredName":"6 MONTH/CYCLE NON-ANTHRACYCLINE REGIMEN","longName":"2565983","preferredDefinition":"6 MONTH/CYCLE NON-ANTHRACYCLINE REGIMEN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CECC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEA670A9-0FBC-0537-E034-0003BA12F5E7","beginDate":"2003-05-27","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Oral CMF","valueDescription":"Oral Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF)","ValueMeaning":{"publicId":"2577053","version":"1","preferredName":"Oral Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF)","longName":"2577053","preferredDefinition":"Oral Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA0A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062A474A-2426-05D0-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","deletedIndicator":"No"},{"value":"IV CMF","valueDescription":"Intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)","ValueMeaning":{"publicId":"2577054","version":"1","preferredName":"Intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)","longName":"2577054","preferredDefinition":"Intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA0B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062A4FC8-080E-05C4-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ONEDATA","dateModified":"2005-11-22","deletedIndicator":"No"},{"value":"Standard AC","valueDescription":"standard anthracycline and cyclophosphamide (AC) therapy ","ValueMeaning":{"publicId":"2577056","version":"1","preferredName":"standard anthracycline and cyclophosphamide (AC) therapy ","longName":"2577056","preferredDefinition":"standard anthracycline and cyclophosphamide (AC) therapy ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA0D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062A4FC8-0812-05C4-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"PWEST","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Dose dense AC","valueDescription":"dose dense anthracycline (doxorubicin) and cyclophosphamide (AC) therapy","ValueMeaning":{"publicId":"2577058","version":"1","preferredName":"dose dense anthracycline (doxorubicin) and cyclophosphamide (AC) therapy","longName":"2577058","preferredDefinition":"dose dense (DD or delivery of multiple cycles of chemotherapy using\r\nthe shortest possible intervals) anthracycline (doxorubicin) and cyclophosphamide (AC) therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0629F979-A229-0B06-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"PWEST","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Standard AC followed by a taxane","valueDescription":"standard anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane","ValueMeaning":{"publicId":"2577059","version":"1","preferredName":"standard anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane","longName":"2577059","preferredDefinition":"standard anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane (antimitotic or antimicrotubule agents or mitotic inhibitors such as docetaxel and paclitaxel).\r\n","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062B1462-8DC9-13F5-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"PWEST","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Dose dense AC followed by a taxane","valueDescription":"dose dense anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane","ValueMeaning":{"publicId":"2577061","version":"1","preferredName":"dose dense anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane","longName":"2577061","preferredDefinition":"dose dense (DD or delivery of multiple cycles of chemotherapy using the shortest possible intervals) anthracycline (doxorubicin) and cyclophosphamide (AC) followed by a taxane (antimitotic or antimicrotubule agents or mitotic inhibitors such as docetaxel and paclitaxel)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA12-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062BB097-A680-6465-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"PWEST","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"FEC","valueDescription":"5-fluorouracil, epirubicin, cyclophosphamide (FEC)","ValueMeaning":{"publicId":"2577062","version":"1","preferredName":"5-fluorouracil, epirubicin, cyclophosphamide (FEC)","longName":"2577062","preferredDefinition":"5-fluorouracil, epirubicin, cyclophosphamide (FEC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA13-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062BC62F-27ED-6461-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ONEDATA","dateModified":"2005-11-22","deletedIndicator":"No"},{"value":"TAC","valueDescription":"Doxorubicin, cyclophosphamide, and Docetaxel (TAC)","ValueMeaning":{"publicId":"2569617","version":"1","preferredName":"Doxorubicin, cyclophosphamide, and Docetaxel (TAC)","longName":"2569617","preferredDefinition":"Doxorubicin, cyclophosphamide, and Docetaxel (TAC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCFE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-05-19","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062BC62F-27F0-6461-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ONEDATA","dateModified":"2005-11-22","deletedIndicator":"No"},{"value":"Other regimen given as part of a CTSU adjuvant therapy protocol","valueDescription":"other regimen given as part of a CTSU adjuvant therapy protocol","ValueMeaning":{"publicId":"2577063","version":"1","preferredName":"other regimen given as part of a CTSU adjuvant therapy protocol","longName":"2577063","preferredDefinition":"other regimen given as part of a CTSU adjuvant therapy protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ALAIS","dateModified":"2005-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062BB097-A684-6465-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"PWEST","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062BC62F-27F2-6461-E044-0003BA3F9857","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"ONEDATA","dateModified":"2005-11-22","deletedIndicator":"No"},{"value":"Carboplatin and Paclitaxel","valueDescription":"Carboplatin and Paclitaxel","ValueMeaning":{"publicId":"2577315","version":"1","preferredName":"Carboplatin and Paclitaxel","longName":"2577315","preferredDefinition":"Regimen 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FB10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"SHIDED","dateModified":"2005-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"089B1253-D8C7-3401-E044-0003BA3F9857","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"ONEDATA","dateModified":"2005-12-23","deletedIndicator":"No"},{"value":"Cisplatin and Vinorelbine","valueDescription":"Cisplatin and Vinorelbine","ValueMeaning":{"publicId":"2577316","version":"1","preferredName":"Cisplatin and Vinorelbine","longName":"2577316","preferredDefinition":"Regimen 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FB11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"SHIDED","dateModified":"2005-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"089B1253-D8CB-3401-E044-0003BA3F9857","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"ONEDATA","dateModified":"2005-12-23","deletedIndicator":"No"},{"value":"Cisplatin and Docetaxel","valueDescription":"Cisplatin and Docetaxel","ValueMeaning":{"publicId":"2577317","version":"1","preferredName":"Cisplatin and Docetaxel","longName":"2577317","preferredDefinition":"Regimen 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FB12-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"SHIDED","dateModified":"2005-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"089B1253-D8CF-3401-E044-0003BA3F9857","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"ONEDATA","dateModified":"2005-12-23","deletedIndicator":"No"},{"value":"Cisplatin and Gemcitabine","valueDescription":"Cisplatin and Gemcitabine","ValueMeaning":{"publicId":"2577318","version":"1","preferredName":"Cisplatin and Gemcitabine","longName":"2577318","preferredDefinition":"Regimen 4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FB13-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"SHIDED","dateModified":"2005-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"089B1253-D8D3-3401-E044-0003BA3F9857","beginDate":"2005-12-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-12-23","modifiedBy":"ONEDATA","dateModified":"2005-12-23","deletedIndicator":"No"},{"value":"Cisplatin and 5-Fluorouracil","valueDescription":"Cisplatin and 5-Fluorouracil","ValueMeaning":{"publicId":"2580412","version":"1","preferredName":"Cisplatin and 5-Fluorouracil","longName":"2580412","preferredDefinition":"Regimen 5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0729-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-02","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-02","modifiedBy":"ALAIS","dateModified":"2006-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A09938F-74BC-4B11-E044-0003BA3F9857","beginDate":"2006-08-02","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-02","modifiedBy":"ONEDATA","dateModified":"2006-08-02","deletedIndicator":"No"},{"value":"TC","valueDescription":"Docetaxel and cyclophosphamide (TC) therapy","ValueMeaning":{"publicId":"2580756","version":"1","preferredName":"Docetaxel and cyclophosphamide (TC) therapy","longName":"2580756","preferredDefinition":"docetaxel (Taxotere) and cyclophosphamide (TC) therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0881-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-09-06","modifiedBy":"PWEST","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CC989ED-7C3E-11E5-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"Chemotherapy not given","valueDescription":"NOT GIVEN","ValueMeaning":{"publicId":"2562260","version":"1","preferredName":"NOT GIVEN","longName":"2562260","preferredDefinition":"NOT GIVEN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C041-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-08-06","endDate":null,"createdBy":"PWEST","dateCreated":"2002-08-06","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CCB84B1-55E4-5FBC-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"PWEST","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","deletedIndicator":"No"},{"value":"AC","valueDescription":"cyclophosphamide plus doxorubicin","ValueMeaning":{"publicId":"2672468","version":"1","preferredName":"cyclophosphamide plus doxorubicin","longName":"2672468","preferredDefinition":"cyclophosphamide plus doxorubicin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA4DF3-DB59-4E21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C681-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"AC followed by a Taxane ","valueDescription":"cyclophosphamide plus doxorubicin followed by a Taxane","ValueMeaning":{"publicId":"2672469","version":"1","preferredName":"cyclophosphamide plus doxorubicin followed by a Taxane","longName":"2672469","preferredDefinition":"cyclophosphamide plus doxorubicin followed by a Taxane","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37A9899E-BA75-53A7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C693-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"CAF","valueDescription":"Cyclophosphamide, doxorubicin and fluorouracil","ValueMeaning":{"publicId":"2672470","version":"1","preferredName":"Cyclophosphamide, doxorubicin and fluorouracil","longName":"2672470","preferredDefinition":"Cyclophosphamide, doxorubicin and fluorouracil","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37A99FB0-393B-5A7D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C6A5-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"CEF","valueDescription":"Cyclophosphamide, Epirubicin and Fluorouracil","ValueMeaning":{"publicId":"2672471","version":"1","preferredName":"Cyclophosphamide, Epirubicin and Fluorouracil","longName":"2672471","preferredDefinition":"Cyclophosphamide, Epirubicin and Fluorouracil","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA4DF3-DB69-4E21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C6B7-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"FOLFOX","valueDescription":"5-Fluorouracil, Leucovorin and Oxaliplatin ","ValueMeaning":{"publicId":"2672472","version":"1","preferredName":"5-Fluorouracil, Leucovorin and Oxaliplatin ","longName":"2672472","preferredDefinition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX Regimen","conceptCode":"C11197","definition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA742C-2021-5B9C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept_ghd_11.16.17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C6C9-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"FOLFIRI","valueDescription":"Fluorouracil, leucovorin, and irinotecan","ValueMeaning":{"publicId":"2672473","version":"1","preferredName":"Fluorouracil, leucovorin, and irinotecan","longName":"2672473","preferredDefinition":"Fluorouracil, leucovorin, and irinotecan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37A9AE59-30EF-00BA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37A9A62C-C6DB-5BD3-E044-0003BA3F9857","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"ONEDATA","dateModified":"2007-08-14","deletedIndicator":"No"},{"value":"Dose dense","valueDescription":"Dose dense chemotherapy regimen","ValueMeaning":{"publicId":"2582000","version":"1","preferredName":"Dose dense chemotherapy regimen","longName":"2582000","preferredDefinition":"Dose dense chemotherapy regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-20","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-20","modifiedBy":"PWEST","dateModified":"2006-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B3AB7A-39DF-4F0A-E044-0003BA3F9857","beginDate":"2006-11-20","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-20","modifiedBy":"ONEDATA","dateModified":"2006-11-20","deletedIndicator":"No"},{"value":"Classical","valueDescription":"Standard chemotherapy regimen","ValueMeaning":{"publicId":"2581999","version":"1","preferredName":"Standard chemotherapy regimen","longName":"2581999","preferredDefinition":"Standard chemotherapy regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-20","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-20","modifiedBy":"PWEST","dateModified":"2006-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B3AB7A-39F1-4F0A-E044-0003BA3F9857","beginDate":"2006-11-20","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-20","modifiedBy":"ONEDATA","dateModified":"2006-11-20","deletedIndicator":"No"},{"value":"Taxane-containing","valueDescription":"Taxane-containing","ValueMeaning":{"publicId":"2764773","version":"1","preferredName":"Taxane-containing","longName":"2764773","preferredDefinition":"Taxane-containing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"519DBC63-C1B6-23CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"519DBF30-895B-242F-E044-0003BA3F9857","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","deletedIndicator":"No"},{"value":"Non-taxane containing","valueDescription":"Non-taxane containing","ValueMeaning":{"publicId":"2764774","version":"1","preferredName":"Non-taxane containing","longName":"2764774","preferredDefinition":"Non-taxane containing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"519DBD49-1A32-22D4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"519DBF30-896D-242F-E044-0003BA3F9857","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"NOT APPLICABLE ","ValueMeaning":{"publicId":"2560935","version":"1","preferredName":"NOT APPLICABLE ","longName":"2560935","preferredDefinition":"NOT APPLICABLE ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"519DBF30-897F-242F-E044-0003BA3F9857","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","deletedIndicator":"No"},{"value":"Cisplatin and pemetrexed","valueDescription":"Cisplatin and pemetrexed","ValueMeaning":{"publicId":"2794309","version":"1","preferredName":"Cisplatin and pemetrexed","longName":"2794309","preferredDefinition":"Cisplatin and pemetrexed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59C2EFB2-9B5F-68C6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-10-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59C2F074-65EA-68F2-E044-0003BA3F9857","beginDate":"2008-10-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-10-21","modifiedBy":"ONEDATA","dateModified":"2008-10-21","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"CAPECITABINE","ValueMeaning":{"publicId":"2561705","version":"1","preferredName":"CAPECITABINE","longName":"2561705v1.00","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE16-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"CLOHNES","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657F8DE9-E05C-314B-E040-BB89AD436227","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Other Chemotherapy Agents","valueDescription":"Other Chemotherapy Agents","ValueMeaning":{"publicId":"2853309","version":"1","preferredName":"Other Chemotherapy Agents","longName":"2853309","preferredDefinition":"Other Chemotherapy Agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"657C1DA4-379C-46C8-E040-BB89AD437C19","latestVersionIndicator":"Yes","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-37B5-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"CYCLOPHOSPHAMIDE","ValueMeaning":{"publicId":"2561009","version":"1","preferredName":"CYCLOPHOSPHAMIDE","longName":"2561009v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-37BF-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Taxane","valueDescription":"Taxane","ValueMeaning":{"publicId":"2853310","version":"1","preferredName":"Taxane","longName":"2853310","preferredDefinition":"Taxane","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"657C1DA4-37C9-46C8-E040-BB89AD437C19","latestVersionIndicator":"Yes","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-37E2-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Anthracycline","valueDescription":"Anthracyclines","ValueMeaning":{"publicId":"2853311","version":"1","preferredName":"Anthracyclines","longName":"2853311","preferredDefinition":"Anthracycline","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"657C1DA4-37EC-46C8-E040-BB89AD437C19","latestVersionIndicator":"Yes","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-3805-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"5-FU/LV-capecitabine alone","valueDescription":"5-FU/LV-capecitabine alone","ValueMeaning":{"publicId":"3098975","version":"1","preferredName":"5-FU/LV-capecitabine alone","longName":"3098975","preferredDefinition":"5-FU/LV-capecitabine alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-4340-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-4359-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"},{"value":"Irinotecan-based therapy","valueDescription":"Irinotecan-based therapy","ValueMeaning":{"publicId":"3098976","version":"1","preferredName":"Irinotecan-based therapy","longName":"3098976","preferredDefinition":"Irinotecan-based therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-4363-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-437C-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"},{"value":"Oxaliplatin based therapy","valueDescription":"Oxaliplatin based therapy","ValueMeaning":{"publicId":"3098977","version":"1","preferredName":"Oxaliplatin based therapy","longName":"3098977","preferredDefinition":"Oxaliplatin based therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-4386-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-439F-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"2567154","version":"1","preferredName":"Cisplatin","longName":"2567154","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D35F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-30","endDate":null,"createdBy":"PFOWLER","dateCreated":"2003-10-30","modifiedBy":"COOPERM","dateModified":"2020-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92FA51CE-05E6-E62D-E040-BB89AD434D12","beginDate":"2010-10-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-19","modifiedBy":"ONEDATA","dateModified":"2010-10-19","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"CBDCA (Carboplatin)","ValueMeaning":{"publicId":"2576636","version":"1","preferredName":"CBDCA (Carboplatin)","longName":"2576636","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F869-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92FA51CE-05F0-E62D-E040-BB89AD434D12","beginDate":"2010-10-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-19","modifiedBy":"ONEDATA","dateModified":"2010-10-19","deletedIndicator":"No"},{"value":"Other chemotherapy regimen","valueDescription":"Other chemotherapy regimen","ValueMeaning":{"publicId":"3144046","version":"1","preferredName":"Other chemotherapy regimen","longName":"3144046","preferredDefinition":"Other chemotherapy regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-6895-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-68AE-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Weekly paclitaxel x 12 followed by 5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC)","valueDescription":"Weekly paclitaxel x 12 followed by 5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC)","ValueMeaning":{"publicId":"3144047","version":"1","preferredName":"Weekly paclitaxel x 12 followed by 5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC)","longName":"3144047","preferredDefinition":"Weekly paclitaxel x 12 followed by 5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-68B8-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-68D1-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC) followed by weekly paclitaxel x 12","valueDescription":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC) followed by weekly paclitaxel x 12","ValueMeaning":{"publicId":"3144048","version":"1","preferredName":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC) followed by weekly paclitaxel x 12","longName":"3144048","preferredDefinition":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide (FAC) followed by weekly paclitaxel x 12","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-68DB-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-68F4-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Docetaxel, doxorubicin, and cyclophosphamide (6 cycles)","valueDescription":"Docetaxel, doxorubicin, and cyclophosphamide (6 cycles)","ValueMeaning":{"publicId":"3144049","version":"1","preferredName":"Docetaxel, doxorubicin, and cyclophosphamide (6 cycles)","longName":"3144049","preferredDefinition":"Docetaxel, doxorubicin, and cyclophosphamide (6 cycles)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-68FE-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-6917-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Dose dense doxorubicin and cyclophosphamide followed by dose dense paclitaxel (q 2 weeks, 4 cycles each)","valueDescription":"Dose dense doxorubicin and cyclophosphamide followed by dose dense paclitaxel (q 2 weeks, 4 cycles each)","ValueMeaning":{"publicId":"3144050","version":"1","preferredName":"Dose dense doxorubicin and cyclophosphamide followed by dose dense paclitaxel (q 2 weeks, 4 cycles each)","longName":"3144050","preferredDefinition":"Dose dense doxorubicin and cyclophosphamide followed by dose dense paclitaxel (q 2 weeks, 4 cycles each)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-6921-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-693A-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (3 cycles each)","valueDescription":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (3 cycles each)","ValueMeaning":{"publicId":"3144051","version":"1","preferredName":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (3 cycles each)","longName":"3144051","preferredDefinition":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (3 cycles each)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-6944-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-695D-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (q 3 weeks, 4 cycles each)","valueDescription":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (q 3 weeks, 4 cycles each)","ValueMeaning":{"publicId":"3144052","version":"1","preferredName":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (q 3 weeks, 4 cycles each)","longName":"3144052","preferredDefinition":"5-FU, doxorubicin (or epirubicin) and cyclophosphamide followed by docetaxel (q 3 weeks, 4 cycles each)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-6967-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-6980-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by weekly paclitaxel x 12","valueDescription":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by weekly paclitaxel x 12","ValueMeaning":{"publicId":"3144053","version":"1","preferredName":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by weekly paclitaxel x 12","longName":"3144053","preferredDefinition":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by weekly paclitaxel x 12","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-698A-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-69A3-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by paclitaxel","valueDescription":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by paclitaxel","ValueMeaning":{"publicId":"3144054","version":"1","preferredName":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by paclitaxel","longName":"3144054","preferredDefinition":"Doxorubicin (or epirubicin) and cyclophosphamide (AC/EC) followed by paclitaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-69AD-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-69C6-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"5-FU, doxorubicin (or epirubicin), and cyclophosphamide","valueDescription":"5-FU, doxorubicin (or epirubicin), and cyclophosphamide","ValueMeaning":{"publicId":"3144055","version":"1","preferredName":"5-FU, doxorubicin (or epirubicin), and cyclophosphamide","longName":"3144055","preferredDefinition":"5-FU, doxorubicin (or epirubicin), and cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-69D0-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-69E9-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Docetaxel and cyclophosphamide","valueDescription":"Docetaxel and cyclophosphamide","ValueMeaning":{"publicId":"3144056","version":"1","preferredName":"Docetaxel and cyclophosphamide","longName":"3144056","preferredDefinition":"Docetaxel and cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91699773-69F3-B4D4-E040-BB89AD437FB2","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91699773-6A0C-B4D4-E040-BB89AD437FB2","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"MVAC","valueDescription":"Doxorubicin Vinblastine Methotrexate Cisplatin","ValueMeaning":{"publicId":"3153857","version":"1","preferredName":"Doxorubicin Vinblastine Methotrexate Cisplatin","longName":"3153857","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04): A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04): An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04): An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94023F5E-7FA7-E4F2-E040-BB89AD432359","latestVersionIndicator":"Yes","beginDate":"2010-11-01","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94023F5E-7FC0-E4F2-E040-BB89AD432359","beginDate":"2010-11-01","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-01","modifiedBy":"ONEDATA","dateModified":"2010-11-01","deletedIndicator":"No"},{"value":"Paclitaxel","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94023F5E-7FCA-E4F2-E040-BB89AD432359","beginDate":"2010-11-01","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-01","modifiedBy":"ONEDATA","dateModified":"2010-11-01","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"3145831","version":"1","preferredName":"Gemcitabine","longName":"3145831","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A1DB-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94023F5E-7FD4-E4F2-E040-BB89AD432359","beginDate":"2010-11-01","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-01","modifiedBy":"ONEDATA","dateModified":"2010-11-01","deletedIndicator":"No"},{"value":"AC - WP: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (IV) followed by paclitaxel 80 mg/m2 (IV)","valueDescription":"AC - WP: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (IV) followed by paclitaxel 80 mg/m2 (IV)","ValueMeaning":{"publicId":"3155362","version":"1","preferredName":"AC - WP: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (IV) followed by paclitaxel 80 mg/m2 (IV)","longName":"3155362","preferredDefinition":"AC WP: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (IV) followed by paclitaxel 80 mg/m2 (IV)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"942A8410-59FE-B9F8-E040-BB89AD435665","latestVersionIndicator":"Yes","beginDate":"2010-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"942A8410-5A17-B9F8-E040-BB89AD435665","beginDate":"2010-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-03","modifiedBy":"ONEDATA","dateModified":"2010-11-03","deletedIndicator":"No"},{"value":"TC: docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 (IV)","valueDescription":"TC: docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 (IV)","ValueMeaning":{"publicId":"3155363","version":"1","preferredName":"TC: docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 (IV)","longName":"3155363","preferredDefinition":"TC: docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 (IV)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"942A8410-5A21-B9F8-E040-BB89AD435665","latestVersionIndicator":"Yes","beginDate":"2010-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"942A8410-5A3A-B9F8-E040-BB89AD435665","beginDate":"2010-11-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-03","modifiedBy":"ONEDATA","dateModified":"2010-11-03","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9998-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"5-FU or capecitabine","valueDescription":"5-FU or capecitabine","ValueMeaning":{"publicId":"3185003","version":"1","preferredName":"5-FU or capecitabine","longName":"3185003","preferredDefinition":"5-FU or capecitabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4A1E1E-99A2-CF75-E040-BB89AD433EF9","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-99BB-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Irinotecan","valueDescription":"Irinotecan","ValueMeaning":{"publicId":"2574348","version":"1","preferredName":"Irinotecan","longName":"2574348","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan","conceptCode":"C62040","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-07","modifiedBy":"HARTLEYG","dateModified":"2017-11-16","changeDescription":"Added concept code_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-99C5-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-99CF-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Cetuximab or panitumumab","valueDescription":"Panitumumab Cetuximab","ValueMeaning":{"publicId":"3185005","version":"1","preferredName":"Panitumumab Cetuximab","longName":"3185005","preferredDefinition":"A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.: A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panitumumab","conceptCode":"C1857","definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4A1E1E-99DD-CF75-E040-BB89AD433EF9","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-99F6-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Carboplatin and 5-Fluorouracil","valueDescription":"Carboplatin and 5-Fluorouracil","ValueMeaning":{"publicId":"3282700","version":"1","preferredName":"Carboplatin and 5-Fluorouracil","longName":"3282700","preferredDefinition":"Carboplatin and 5-Fluorouracil","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD77884E-B039-EEB1-E040-BB89AD437C81","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD77884E-B052-EEB1-E040-BB89AD437C81","beginDate":"2011-09-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-21","modifiedBy":"ONEDATA","dateModified":"2011-09-21","deletedIndicator":"No"},{"value":"Carboplatin and Docetaxel","valueDescription":"Carboplatin and Docetaxel","ValueMeaning":{"publicId":"3282701","version":"1","preferredName":"Carboplatin and Docetaxel","longName":"3282701","preferredDefinition":"Carboplatin and Docetaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD77884E-B05C-EEB1-E040-BB89AD437C81","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD77884E-B075-EEB1-E040-BB89AD437C81","beginDate":"2011-09-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-21","modifiedBy":"ONEDATA","dateModified":"2011-09-21","deletedIndicator":"No"},{"value":"DD AC - DD P: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 175 mg/m2","valueDescription":"DD AC - DD P: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 175 mg/m2","ValueMeaning":{"publicId":"3411456","version":"1","preferredName":"DD AC - DD P: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 175 mg/m2","longName":"3411456","preferredDefinition":"DD AC - DD P: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 175 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAADC058-F178-6672-E040-BB89AD436AB1","latestVersionIndicator":"Yes","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAADC058-F191-6672-E040-BB89AD436AB1","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"ONEDATA","dateModified":"2012-03-07","deletedIndicator":"No"},{"value":"DD AC - WP: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 80 mg/m2","valueDescription":"DD AC - WP: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 80 mg/m2","ValueMeaning":{"publicId":"3411457","version":"1","preferredName":"DD AC - WP: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 80 mg/m2","longName":"3411457","preferredDefinition":"DD AC - WP: doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 followed by paclitaxel 80 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAADC058-F19B-6672-E040-BB89AD436AB1","latestVersionIndicator":"Yes","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAADC058-F1B4-6672-E040-BB89AD436AB1","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"ONEDATA","dateModified":"2012-03-07","deletedIndicator":"No"},{"value":"TAC: doxorubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2 plus docetaxel 75 mg/m2","valueDescription":"TAC: doxorubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2 plus docetaxel 75 mg/m2","ValueMeaning":{"publicId":"3411458","version":"1","preferredName":"TAC: doxorubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2 plus docetaxel 75 mg/m2","longName":"3411458","preferredDefinition":"TAC: doxorubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2 plus docetaxel 75 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAADC058-F1BE-6672-E040-BB89AD436AB1","latestVersionIndicator":"Yes","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAADC058-F1D7-6672-E040-BB89AD436AB1","beginDate":"2012-03-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-07","modifiedBy":"ONEDATA","dateModified":"2012-03-07","deletedIndicator":"No"},{"value":"DD AC - DD P","valueDescription":"DD AC - DD P","ValueMeaning":{"publicId":"3553799","version":"1","preferredName":"DD AC - DD P","longName":"3553799","preferredDefinition":"DD AC - DD P","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7285211-7CFE-C508-E040-BB89AD433159","latestVersionIndicator":"Yes","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7285211-7D17-C508-E040-BB89AD433159","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"ONEDATA","dateModified":"2012-08-13","deletedIndicator":"No"},{"value":"DD AC - WP","valueDescription":"DD AC - WP","ValueMeaning":{"publicId":"3553800","version":"1","preferredName":"DD AC - WP","longName":"3553800","preferredDefinition":"DD AC - WP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7285211-7D21-C508-E040-BB89AD433159","latestVersionIndicator":"Yes","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7285211-7D3A-C508-E040-BB89AD433159","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"ONEDATA","dateModified":"2012-08-13","deletedIndicator":"No"},{"value":"AC - WP","valueDescription":"AC - WP","ValueMeaning":{"publicId":"3553801","version":"1","preferredName":"AC - WP","longName":"3553801","preferredDefinition":"AC - WP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7285211-7D44-C508-E040-BB89AD433159","latestVersionIndicator":"Yes","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7285211-7D5D-C508-E040-BB89AD433159","beginDate":"2012-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-13","modifiedBy":"ONEDATA","dateModified":"2012-08-13","deletedIndicator":"No"},{"value":"Cisplatin and Etoposide","valueDescription":"Cisplatin and Etoposide","ValueMeaning":{"publicId":"3645446","version":"1","preferredName":"Cisplatin and Etoposide","longName":"3645446","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0D2E961-F42B-6B4F-E040-BB89AD431228","latestVersionIndicator":"Yes","beginDate":"2012-12-14","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0D2E961-F444-6B4F-E040-BB89AD431228","beginDate":"2012-12-14","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-12-14","modifiedBy":"ONEDATA","dateModified":"2012-12-14","deletedIndicator":"No"},{"value":"Tyrosine Kinase Inhibitors","valueDescription":"Tyrosine Kinase Inhibitors","ValueMeaning":{"publicId":"3861251","version":"1","preferredName":"Tyrosine Kinase Inhibitors","longName":"3861251","preferredDefinition":"Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling, and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain; and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases. (Dictionary of Cell and Molecular Biology Online)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protein Tyrosine Kinase","conceptCode":"C17020","definition":"Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling, and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain; and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases. (Dictionary of Cell and Molecular Biology Online)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-1352-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-136B-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Differentiating agents","valueDescription":"Differentiating agents","ValueMeaning":{"publicId":"3861252","version":"1","preferredName":"Differentiating agents","longName":"3861252","preferredDefinition":"Differentiating agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-1375-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-138E-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Proteasome Inhibitors","valueDescription":"Proteasome Inhibitors","ValueMeaning":{"publicId":"3861253","version":"1","preferredName":"Proteasome Inhibitors","longName":"3861253","preferredDefinition":"Proteolytic complexes, proteolytic core of the proteasome system, that degrade cytosolic and nuclear proteins are implicated in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cells. The 20S proteasome (700 kD), essential in ATP ubiquitin degradation pathway, has 13-15 subunits each of which has three or four different peptidase activities. The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the degradation of ubiquitinated cellular proteins and certain non-ubiquitinated proteins. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proteasome","conceptCode":"C13314","definition":"Proteolytic complexes, proteolytic core of the proteasome system, that degrade cytosolic and nuclear proteins are implicated in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cells. The 20S proteasome (700 kD), essential in ATP ubiquitin degradation pathway, has 13-15 subunits each of which has three or four different peptidase activities. The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the degradation of ubiquitinated cellular proteins and certain non-ubiquitinated proteins. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-139A-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-13B3-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Vinca alkaloids","valueDescription":"Vinca Alkaloids","ValueMeaning":{"publicId":"3861255","version":"1","preferredName":"Vinca Alkaloids","longName":"3861255","preferredDefinition":"A type of drug that blocks cell growth by stopping mitosis (cell division). Vinca alkaloids interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A vinca alkaloid is a type of mitotic inhibitor and a type of antimicrotubule agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinca Alkaloid Compound","conceptCode":"C932","definition":"A type of drug that blocks cell growth by stopping mitosis (cell division). Vinca alkaloids interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A vinca alkaloid is a type of mitotic inhibitor and a type of antimicrotubule agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-13C0-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-13D9-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Oral Antimetabolites","valueDescription":"Oral Antimetabolites","ValueMeaning":{"publicId":"3861256","version":"1","preferredName":"Oral Antimetabolites","longName":"3861256","preferredDefinition":"Oral; of, or relating to, or affecting, or for use in the mouth.: Agents that inhibit the biosynthesis of pyrimidine or purine nucleotides or mimic natural nucleotides so they interfere with their synthesis or function and subsequently interrupt DNA, RNA, and/or protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral","conceptCode":"C25311","definition":"Of, or relating to, or affecting, or for use in the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antimetabolite","conceptCode":"C272","definition":"An antineoplastic agent with a structural similarity to a natural substance that can replace that substance in a normal biochemical pathway and interfere with the normal metabolic processes of cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-13E6-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-13FF-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Topoisomerase Inhibitors","valueDescription":"Topoisomerase Inhibitors","ValueMeaning":{"publicId":"2918780","version":"1","preferredName":"Topoisomerase Inhibitors","longName":"2918780","preferredDefinition":"Compounds that inhibit the enzymatic activity of topoisomerases.  Topoisomerases I and II are involved in the interconversion of DNA forms differing in their linking number \"L\".  Topoisomerase I acts by introducing transient nicks in the DNA, while topoisomerase II acts via intermediates containing double-stranded DNA cuts and requires ATP for its action.  The change in linking number (delta L) serves to measure the topological changes occurring in DNA during structural transformations (e.g. palindrome extrusion, Z-DNA formation, transcription factor binding, transcription).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase Inhibitor","conceptCode":"C1748","definition":"Any substance that inhibits topoisomerase, an enzyme that cleaves the DNA backbone to relieve torsional stress in a DNA molecule generated during replication, transcription, and other structural transformations. Inhibition of topoisomerase causes DNA damage, inhibition of DNA replication, and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6EA4F27E-2F1B-6FF8-E040-BB89AD433DB7","latestVersionIndicator":"Yes","beginDate":"2009-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-1413-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroids","ValueMeaning":{"publicId":"2578061","version":"1","preferredName":"Corticosteroids","longName":"2578061","preferredDefinition":"Hormones that have antitumor activity in lymphomas and lymphoid leukemias; in addition, corticosteroids (steroids) may be used for hormone replacement and for the management of some of the complications of cancer and its treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Corticosteroid","conceptCode":"C211","definition":"Any steroid hormone made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDFA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-01","modifiedBy":"CAMPBELB","dateModified":"2013-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-141D-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Alkylators","valueDescription":"Alkylators","ValueMeaning":{"publicId":"3861258","version":"1","preferredName":"Alkylators","longName":"3861258","preferredDefinition":"Alkylators","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-1434-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-144D-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"IV Antimetabolites","valueDescription":"IV Antimetabolite","ValueMeaning":{"publicId":"3861265","version":"1","preferredName":"IV Antimetabolite","longName":"3861265","preferredDefinition":"(in-tra-VEE-nus) IV. Within a blood vessel.: Agents that inhibit the biosynthesis of pyrimidine or purine nucleotides or mimic natural nucleotides so they interfere with their synthesis or function and subsequently interrupt DNA, RNA, and/or protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antimetabolite","conceptCode":"C272","definition":"An antineoplastic agent with a structural similarity to a natural substance that can replace that substance in a normal biochemical pathway and interfere with the normal metabolic processes of cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E9935-145E-7383-E040-BB89AD433F41","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E9935-1477-7383-E040-BB89AD433F41","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Anthracycline and cyclophosphamide (AC)","valueDescription":"Anthracycline and cyclophosphamide (AC)","ValueMeaning":{"publicId":"3916116","version":"1","preferredName":"Anthracycline and cyclophosphamide (AC)","longName":"3916116","preferredDefinition":"Anthracycline and cyclophosphamide (AC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-7F4A-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E84FDE31-7F63-3FE9-E040-BB89AD4320EF","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Cisplatin-containing regimen","valueDescription":"Cisplatin-containing regimen","ValueMeaning":{"publicId":"3916117","version":"1","preferredName":"Cisplatin-containing regimen","longName":"3916117","preferredDefinition":"Cisplatin-containing regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-7F6D-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E84FDE31-7F86-3FE9-E040-BB89AD4320EF","beginDate":"2013-10-09","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Enzymes","valueDescription":"Enzymes","ValueMeaning":{"publicId":"3861234","version":"1","preferredName":"Enzymes","longName":"3861234","preferredDefinition":"A protein that speeds up chemical reactions in the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzyme","conceptCode":"C16554","definition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47E5B54-79BF-1307-E040-BB89AD43561F","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E47E5B54-79D8-1307-E040-BB89AD43561F","beginDate":"2013-08-21","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-21","modifiedBy":"ONEDATA","dateModified":"2013-08-21","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other, specify","ValueMeaning":{"publicId":"2570886","version":"1","preferredName":"Other, specify","longName":"2570886","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E1F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CAMPBELB","dateModified":"2013-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5314422-7758-2307-E040-BB89AD434B47","beginDate":"2013-08-30","endDate":null,"createdBy":"TSANE","dateCreated":"2013-08-30","modifiedBy":"ONEDATA","dateModified":"2013-08-30","deletedIndicator":"No"},{"value":"Gemcitabine 1000 mg/m2 day 1 and day 8 + Carboplatin AUC 4 day 1 every 21 days","valueDescription":"Gemcitabine 1000 mg/m2 day 1 and day 8 + Carboplatin AUC 4 day 1 every 21 days","ValueMeaning":{"publicId":"4039388","version":"1","preferredName":"Gemcitabine 1000 mg/m2 day 1 and day 8 + Carboplatin AUC 4 day 1 every 21 days","longName":"4039388","preferredDefinition":"Gemcitabine 1000 mg/m2 day 1 and day 8 + Carboplatin AUC 4 day 1 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF007CB9-32AA-A94D-E040-BB89AD43056C","latestVersionIndicator":"Yes","beginDate":"2014-01-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF007CB9-32C3-A94D-E040-BB89AD43056C","beginDate":"2014-01-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-02","modifiedBy":"ONEDATA","dateModified":"2014-01-02","deletedIndicator":"No"},{"value":"Paclitaxel 175 mg/m2 + Carboplatin AUC 5 every 21 days","valueDescription":"Paclitaxel 175 mg/m2 + Carboplatin AUC 5 every 21 days","ValueMeaning":{"publicId":"4039389","version":"1","preferredName":"Paclitaxel 175 mg/m2 + Carboplatin AUC 5 every 21 days","longName":"4039389","preferredDefinition":"Paclitaxel 175 mg/m2 + Carboplatin AUC 5 every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF007CB9-32CD-A94D-E040-BB89AD43056C","latestVersionIndicator":"Yes","beginDate":"2014-01-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF007CB9-32E6-A94D-E040-BB89AD43056C","beginDate":"2014-01-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-02","modifiedBy":"ONEDATA","dateModified":"2014-01-02","deletedIndicator":"No"},{"value":"Adjuvant","valueDescription":"Adjuvant","ValueMeaning":{"publicId":"2570071","version":"1","preferredName":"Adjuvant","longName":"2570071","preferredDefinition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DEC4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"REEVESD","dateModified":"2014-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBE42FE-4F8E-303D-E040-BB89AD433A04","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"ONEDATA","dateModified":"2013-12-17","deletedIndicator":"No"},{"value":"Neo-adjuvant","valueDescription":"Neo-Adjuvant","ValueMeaning":{"publicId":"2570467","version":"1","preferredName":"Neo-Adjuvant","longName":"2570467","preferredDefinition":"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E050-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"REEVESD","dateModified":"2014-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBE42FE-4FA2-303D-E040-BB89AD433A04","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"ONEDATA","dateModified":"2013-12-17","deletedIndicator":"No"},{"value":"Pemetrexed","valueDescription":"Pemetrexed","ValueMeaning":{"publicId":"3237462","version":"1","preferredName":"Pemetrexed","longName":"3237462","preferredDefinition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6570-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCC29A29-15F3-A1F3-E040-BB89AD433071","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"ONEDATA","dateModified":"2014-06-26","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCC29A29-15FD-A1F3-E040-BB89AD433071","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"ONEDATA","dateModified":"2014-06-26","deletedIndicator":"No"},{"value":"Crizotinib","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCC29A29-1607-A1F3-E040-BB89AD433071","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"ONEDATA","dateModified":"2014-06-26","deletedIndicator":"No"},{"value":"Ceritinib","valueDescription":"Ceritinib","ValueMeaning":{"publicId":"4369572","version":"1","preferredName":"Ceritinib","longName":"4369572","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceritinib","conceptCode":"C115112","definition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCC29A29-1614-A1F3-E040-BB89AD433071","latestVersionIndicator":"Yes","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCC29A29-162D-A1F3-E040-BB89AD433071","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"ONEDATA","dateModified":"2014-06-26","deletedIndicator":"No"},{"value":"Afatinib","valueDescription":"Afatinib","ValueMeaning":{"publicId":"3462019","version":"1","preferredName":"Afatinib","longName":"3462019","preferredDefinition":"An orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Afatinib irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afatinib","conceptCode":"C66940","definition":"An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C08DE349-F5AC-1829-E040-BB89AD430889","latestVersionIndicator":"Yes","beginDate":"2012-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCC29A29-1641-A1F3-E040-BB89AD433071","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"ONEDATA","dateModified":"2014-06-26","deletedIndicator":"No"},{"value":"Epirubicin, Cisplatin, and Fluorouracil","valueDescription":"Epirubicin, Cisplatin, and Fluorouracil","ValueMeaning":{"publicId":"4826194","version":"1","preferredName":"Epirubicin, Cisplatin, and Fluorouracil","longName":"4826194","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Epirubicin/Fluorouracil","conceptCode":"C10937","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"160D8CE7-9A52-048E-E050-BB89AD432058","latestVersionIndicator":"Yes","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"160D8CE7-9A6B-048E-E050-BB89AD432058","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"ONEDATA","dateModified":"2015-05-14","deletedIndicator":"No"},{"value":"Epirubicin, Cisplatin, and Capecitabine","valueDescription":"Epirubicin, Cisplatin, and Capecitabine","ValueMeaning":{"publicId":"4826195","version":"1","preferredName":"Epirubicin, Cisplatin, and Capecitabine","longName":"4826195","preferredDefinition":"A regimen consisting of capecitabine, cisplatin and epirubicin that can be used in the treatment of a variety of cancers, such as gastric, ovarian, pancreatic, and esophageal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ECX Regimen","conceptCode":"C141507","definition":"A regimen consisting of capecitabine, cisplatin and epirubicin that can be used in the treatment of a variety of cancers, such as gastric, ovarian, pancreatic, and esophageal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"160D8CE7-9A75-048E-E050-BB89AD432058","latestVersionIndicator":"Yes","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"160D8CE7-9A8E-048E-E050-BB89AD432058","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"ONEDATA","dateModified":"2015-05-14","deletedIndicator":"No"},{"value":"Epirubicin, Oxaliplatin, and Fluorouracil","valueDescription":"Epirubicin, Oxaliplatin, and Fluorouracil","ValueMeaning":{"publicId":"4826196","version":"1","preferredName":"Epirubicin, Oxaliplatin, and Fluorouracil","longName":"4826196","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Epirubicin/Fluorouracil","conceptCode":"C10937","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"160D8CE7-9A98-048E-E050-BB89AD432058","latestVersionIndicator":"Yes","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"160D8CE7-9AB1-048E-E050-BB89AD432058","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"ONEDATA","dateModified":"2015-05-14","deletedIndicator":"No"},{"value":"Epirubicin, Oxaliplatin, and Capecitabine","valueDescription":"Epirubicin, Oxaliplatin, and Capecitabine","ValueMeaning":{"publicId":"4826197","version":"1","preferredName":"Epirubicin, Oxaliplatin, and Capecitabine","longName":"4826197","preferredDefinition":"Epirubicin, Oxaliplatin, and Capecitabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"160D8CE7-9ABB-048E-E050-BB89AD432058","latestVersionIndicator":"Yes","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"160D8CE7-9AD4-048E-E050-BB89AD432058","beginDate":"2015-05-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-05-14","modifiedBy":"ONEDATA","dateModified":"2015-05-14","deletedIndicator":"No"},{"value":"Gemcitabine Alone","valueDescription":"Gemcitabine Single","ValueMeaning":{"publicId":"5153131","version":"1","preferredName":"Gemcitabine Single","longName":"5153131","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: Not accompanied by another or others; exclusive of anyone or anything else.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA15D94-7F05-85A7-E050-BB89AD437035","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA15D94-7F1E-85A7-E050-BB89AD437035","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"Non-oxaliplatin gemcitabine combinations","valueDescription":"Negation Oxaliplatin Gemcitabine Combination","ValueMeaning":{"publicId":"5153132","version":"1","preferredName":"Negation Oxaliplatin Gemcitabine Combination","longName":"5153132","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04): The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.: A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA15D94-7F2D-85A7-E050-BB89AD437035","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA15D94-7F46-85A7-E050-BB89AD437035","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"Folfirinox/ mFolfirinox","valueDescription":"Folfirinox Regimen","ValueMeaning":{"publicId":"5153133","version":"1","preferredName":"Folfirinox Regimen","longName":"5153133","preferredDefinition":"A regimen consisting of fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin used for the treatment of pancreatic cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Folfirinox Regimen","conceptCode":"C11764","definition":"A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, ampullary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA15D94-7F52-85A7-E050-BB89AD437035","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA15D94-7F6B-85A7-E050-BB89AD437035","beginDate":"2016-03-09","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"Pegylated liposomal doxorubicin (30mg/m2) IV on day 1 and Carboplatin (AUC 5) IV on day 1 every 28 days","valueDescription":"Pegylated liposomal doxorubicin (30mg/m2) IV on day 1 and Carboplatin (AUC 5) IV on day 1 every 28 days","ValueMeaning":{"publicId":"5053504","version":"1","preferredName":"Pegylated liposomal doxorubicin (30mg/m2) IV on day 1 and Carboplatin (AUC 5) IV on day 1 every 28 days","longName":"5053504","preferredDefinition":"Pegylated liposomal doxorubicin (30mg/m2) IV on day 1 and Carboplatin (AUC 5) IV on day 1 every 28 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"254B2892-0B5E-7E37-E050-BB89AD431BC8","latestVersionIndicator":"Yes","beginDate":"2015-11-24","endDate":null,"createdBy":"PATELV","dateCreated":"2015-11-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"254B2892-0B77-7E37-E050-BB89AD431BC8","beginDate":"2015-11-24","endDate":null,"createdBy":"PATELV","dateCreated":"2015-11-24","modifiedBy":"ONEDATA","dateModified":"2015-11-24","deletedIndicator":"No"},{"value":"AC + TC","valueDescription":"Doxorubicin And Cyclophosphamide Followed by Docetaxel And Cyclophosphamide","ValueMeaning":{"publicId":"5229281","version":"1","preferredName":"Doxorubicin And Cyclophosphamide Followed by Docetaxel And Cyclophosphamide","longName":"5229281","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: No value exists.: A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): An article","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Followed by","conceptCode":"CL158221","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"3"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31033A1F-E49B-4427-E050-BB89AD434ABF","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31033A1F-E4B4-4427-E050-BB89AD434ABF","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"ONEDATA","dateModified":"2016-04-21","deletedIndicator":"No"},{"value":"EC","valueDescription":"Epirubicin Cyclophosphamide","ValueMeaning":{"publicId":"5229282","version":"1","preferredName":"Epirubicin Cyclophosphamide","longName":"5229282","preferredDefinition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin","conceptCode":"C62028","definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31033A1F-E4C1-4427-E050-BB89AD434ABF","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31033A1F-E4DA-4427-E050-BB89AD434ABF","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"ONEDATA","dateModified":"2016-04-21","deletedIndicator":"No"},{"value":"CMF","valueDescription":"Cyclophosphamide Methotrexate Fluorouracil","ValueMeaning":{"publicId":"5229283","version":"1","preferredName":"Cyclophosphamide Methotrexate Fluorouracil","longName":"5229283","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31033A1F-E4E8-4427-E050-BB89AD434ABF","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31033A1F-E501-4427-E050-BB89AD434ABF","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"ONEDATA","dateModified":"2016-04-21","deletedIndicator":"No"},{"value":"EC + T","valueDescription":"Epirubicin And Cyclophosphamide Followed by Docetaxel","ValueMeaning":{"publicId":"5229284","version":"1","preferredName":"Epirubicin And Cyclophosphamide Followed by Docetaxel","longName":"5229284","preferredDefinition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: No value exists.: A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin","conceptCode":"C62028","definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Followed by","conceptCode":"CL158221","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31033A1F-E511-4427-E050-BB89AD434ABF","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31033A1F-E52A-4427-E050-BB89AD434ABF","beginDate":"2016-04-21","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-21","modifiedBy":"ONEDATA","dateModified":"2016-04-21","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E119C6-5542-34EA-E053-F662850AD74A","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"},{"value":"5-fu/mitomycin","valueDescription":"5-[18F]Fluorouracil Mitomycin","ValueMeaning":{"publicId":"5654491","version":"1","preferredName":"5-[18F]Fluorouracil Mitomycin","longName":"5654491","preferredDefinition":"The fluorine-18 (18F)-radiolabeled pyrimidine analog 5-fluorouracil (5-FU) with positron-emitting activity. Upon administration, 5-[18F]fluorouracil distribution in tumor tissue may be measured with positron emission tomography (PET). The degree of 5-[18F]fluorouracil uptake in tumor tissue may help to predict the response to 5-fluorouracil-based chemotherapy or to determine the response to other therapeutic agents used to treat 5-FU-sensitive tumors.: A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5-[18F]Fluorouracil","conceptCode":"C78203","definition":"The fluorine-18 (18F)-radiolabeled pyrimidine analog 5-fluorouracil (5-FU) with positron-emitting activity. Upon administration, 5-[18F]fluorouracil distribution in tumor tissue may be measured with positron emission tomography (PET). The degree of 5-[18F]fluorouracil uptake in tumor tissue may help to predict the response to 5-fluorouracil-based chemotherapy or to determine the response to other therapeutic agents used to treat 5-FU-sensitive tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E119C6-5550-34EA-E053-F662850AD74A","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"COLBERTM","dateModified":"2021-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E119C6-5569-34EA-E053-F662850AD74A","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"},{"value":"Cisplatin and Fluorouracil","valueDescription":"Cisplatin And Fluorouracil","ValueMeaning":{"publicId":"5628382","version":"1","preferredName":"Cisplatin And Fluorouracil","longName":"5628382","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4635B3FA-2389-2C53-E053-F662850A76D9","latestVersionIndicator":"Yes","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4635B3FA-23A2-2C53-E053-F662850A76D9","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"ONEDATA","dateModified":"2017-01-16","deletedIndicator":"No"},{"value":"Cisplatin and Capecitabine","valueDescription":"Cisplatin And Capecitabine","ValueMeaning":{"publicId":"5628383","version":"1","preferredName":"Cisplatin And Capecitabine","longName":"5628383","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4635B3FA-23B0-2C53-E053-F662850A76D9","latestVersionIndicator":"Yes","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4635B3FA-23C9-2C53-E053-F662850A76D9","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"ONEDATA","dateModified":"2017-01-16","deletedIndicator":"No"},{"value":"Oxaliplatin and Fluorouracil","valueDescription":"Oxaliplatin And Fluorouracil","ValueMeaning":{"publicId":"5628384","version":"1","preferredName":"Oxaliplatin And Fluorouracil","longName":"5628384","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4635B3FA-23D7-2C53-E053-F662850A76D9","latestVersionIndicator":"Yes","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4635B3FA-23F0-2C53-E053-F662850A76D9","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"ONEDATA","dateModified":"2017-01-16","deletedIndicator":"No"},{"value":"Oxaliplatin and Capecitabine","valueDescription":"Oxaliplatin And Capecitabine","ValueMeaning":{"publicId":"5628385","version":"1","preferredName":"Oxaliplatin And Capecitabine","longName":"5628385","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4635B3FA-23FE-2C53-E053-F662850A76D9","latestVersionIndicator":"Yes","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4635B3FA-2417-2C53-E053-F662850A76D9","beginDate":"2017-01-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-01-16","modifiedBy":"ONEDATA","dateModified":"2017-01-16","deletedIndicator":"No"},{"value":"Vinorelbine (Navelbine)","valueDescription":"Vinorelbine","ValueMeaning":{"publicId":"2576638","version":"1","preferredName":"Vinorelbine","longName":"2576638","preferredDefinition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-07B7-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Vinblastine","valueDescription":"Vinblastine","ValueMeaning":{"publicId":"3380287","version":"1","preferredName":"Vinblastine","longName":"3380287","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A492-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-07C1-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Trifluridine and tipiracil (Lonsurf)","valueDescription":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","ValueMeaning":{"publicId":"5831612","version":"1","preferredName":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","longName":"5831612","preferredDefinition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trifluridine and Tipiracil Hydrochloride","conceptCode":"C102554","definition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-07CE-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-07E7-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-07F1-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Sorafenib Tosylate (Nexavar)","valueDescription":"Sorafenib Tosylate","ValueMeaning":{"publicId":"3378376","version":"1","preferredName":"Sorafenib Tosylate","longName":"3378376","preferredDefinition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib Tosylate","conceptCode":"C2194","definition":"The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2F2E-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0805-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Mitoxantrone (Novantrone)","valueDescription":"Mitoxantrone","ValueMeaning":{"publicId":"3518877","version":"1","preferredName":"Mitoxantrone","longName":"3518877","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4110B19-590C-CB86-E040-BB89AD431138","latestVersionIndicator":"Yes","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0819-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Liposomal doxorubicin (Doxil)","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"2576633","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"2576633","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F866-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-082D-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Ixabepilone (Ixempra)","valueDescription":"Ixabepilone","ValueMeaning":{"publicId":"3379090","version":"1","preferredName":"Ixabepilone","longName":"3379090","preferredDefinition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixabepilone","conceptCode":"C37452","definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5681-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0841-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Irinotecan liposome (Onivyde)","valueDescription":"Liposomal Irinotecan","ValueMeaning":{"publicId":"5831614","version":"1","preferredName":"Liposomal Irinotecan","longName":"5831614","preferredDefinition":"A liposomal formulation of the hydrochloride salt of the semisynthetic camptothecin analogue irinotecan with potential antineoplastic activity. During the S phase of the cell cycle, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan Sucrosofate","conceptCode":"C82676","definition":"A liposomal formulation of the semisynthetic camptothecin analogue irinotecan with potential antineoplastic activity. During the S phase of the cell cycle, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-084E-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0867-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Ifosfamide","valueDescription":"Ifosfamide","ValueMeaning":{"publicId":"2739548","version":"1","preferredName":"Ifosfamide","longName":"2739548","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01A4-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0871-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Gemcitabine abraxane (nab-paclitaxel)","valueDescription":"Gemcitabine/Nab-paclitaxel (Abraxane)","ValueMeaning":{"publicId":"5831615","version":"1","preferredName":"Gemcitabine/Nab-paclitaxel (Abraxane)","longName":"5831615","preferredDefinition":"A chemotherapy regimen consisting of gemcitabine and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that can be used for the treatment of metastatic/advanced pancreatic cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GNP Regimen","conceptCode":"C134623","definition":"A chemotherapy regimen consisting of gemcitabine and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that can be used for the treatment of ampullary adenocarcinoma and metastatic/advanced pancreatic cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-087B-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0894-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Etoposide (VP-16)","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-089E-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Eribulin (Halaven)","valueDescription":"Eribulin","ValueMeaning":{"publicId":"4311896","version":"1","preferredName":"Eribulin","longName":"4311896","preferredDefinition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eribulin","conceptCode":"C96748","definition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96171AF-8CBE-CD50-E040-BB89AD436A46","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-08B2-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Epirubicin (Pharmorubicin)","valueDescription":"Epirubicin","ValueMeaning":{"publicId":"2757913","version":"1","preferredName":"Epirubicin","longName":"2757913","preferredDefinition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin","conceptCode":"C62028","definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-841F-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-08C6-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Doxorubicin (Adriamycin)","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-08DA-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Cisplatin Methotrexate","valueDescription":"Cisplatin/Methotrexate","ValueMeaning":{"publicId":"5831617","version":"1","preferredName":"Cisplatin/Methotrexate","longName":"5831617","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Methotrexate","conceptCode":"C10285","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-08E7-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBE47AA-0900-1C05-E053-F662850AE460","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"Capecitabine + Bevacizumab","valueDescription":"Capecitabine/Bevacizumab Regimen","ValueMeaning":{"publicId":"5935682","version":"1","preferredName":"Capecitabine/Bevacizumab Regimen","longName":"5935682","preferredDefinition":"A chemoimmunotherapy regimen consisting of capecitabine and bevacizumab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab/Capecitabine Regimen","conceptCode":"C136243","definition":"A regimen consisting of bevacizumab and capecitabine that may be used for the treatment of colorectal cancer, small bowel , ampullary and appendiceal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5709E437-0FA9-7452-E053-F662850A5252","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5709E437-0FC2-7452-E053-F662850A5252","beginDate":"2017-08-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","deletedIndicator":"No"},{"value":"FOLFOX + Bevacizumab","valueDescription":"FOLFOX/Bevacizumab Regimen","ValueMeaning":{"publicId":"5935684","version":"1","preferredName":"FOLFOX/Bevacizumab Regimen","longName":"5935684","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus bevacizumab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX-Bevacizumab Regimen","conceptCode":"C136248","definition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus bevacizumab that is used for the treatment of colon cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5709E437-0FCF-7452-E053-F662850A5252","latestVersionIndicator":"Yes","beginDate":"2017-08-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5709E437-0FE8-7452-E053-F662850A5252","beginDate":"2017-08-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-18","modifiedBy":"ONEDATA","dateModified":"2017-08-18","deletedIndicator":"No"},{"value":"T-DM1","valueDescription":"Trastuzumab Emtansine","ValueMeaning":{"publicId":"4255113","version":"1","preferredName":"Trastuzumab Emtansine","longName":"4255113","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab Emtansine","conceptCode":"C82492","definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AA2DE6-BE47-4E55-E040-BB89AD43059A","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-4FEC-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"TCHP","valueDescription":"Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen","ValueMeaning":{"publicId":"6005249","version":"1","preferredName":"Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen","longName":"6005249","preferredDefinition":"A chemotherapy regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCHP Regimen","conceptCode":"C138047","definition":"A regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-4FF9-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-5012-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"THP","valueDescription":"Pertuzumab/Trastuzumab/Paclitaxel Regimen","ValueMeaning":{"publicId":"6005251","version":"1","preferredName":"Pertuzumab/Trastuzumab/Paclitaxel Regimen","longName":"6005251","preferredDefinition":"A chemotherapy regimen consisting of pertuzumab, trastuzumab and paclitaxel, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel/Pertuzumab/Trastuzumab Regimen","conceptCode":"C138045","definition":"A chemotherapy regimen consisting of pertuzumab, trastuzumab and paclitaxel, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-501F-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-5038-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"TCH","valueDescription":"TCH Regimen","ValueMeaning":{"publicId":"6005253","version":"1","preferredName":"TCH Regimen","longName":"6005253","preferredDefinition":"A chemotherapy regimen consisting of docetaxel, carboplatin and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCH Regimen","conceptCode":"C63424","definition":"A regimen consisting of docetaxel, carboplatin and trastuzumab that can be used in the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-5045-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-505E-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"TH","valueDescription":"Paclitaxel/Trastuzumab Regimen","ValueMeaning":{"publicId":"6005255","version":"1","preferredName":"Paclitaxel/Trastuzumab Regimen","longName":"6005255","preferredDefinition":"A chemotherapy regimen consisting of paclitaxel and trastuzumab, used as an adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel/Trastuzumab Regimen","conceptCode":"C138051","definition":"A chemotherapy regimen consisting of paclitaxel and trastuzumab, used as an adjuvant treatment for HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-506B-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-5084-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"AC-TH","valueDescription":"Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen","ValueMeaning":{"publicId":"6005257","version":"1","preferredName":"Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen","longName":"6005257","preferredDefinition":"A dose-dense chemotherapy regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen","conceptCode":"C138036","definition":"A dose-dense chemotherapy regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-5091-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-50AA-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"AC-T","valueDescription":"AC-T Regimen","ValueMeaning":{"publicId":"6005259","version":"1","preferredName":"AC-T Regimen","longName":"6005259","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AC-T Regimen","conceptCode":"C63427","definition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-50B7-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-50D0-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"ACTH-P","valueDescription":"AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen","ValueMeaning":{"publicId":"6005261","version":"1","preferredName":"AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen","longName":"6005261","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen","conceptCode":"C138032","definition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-50DD-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-50F6-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"AC-D","valueDescription":"AC Followed by Docetaxel Regimen","ValueMeaning":{"publicId":"6005263","version":"1","preferredName":"AC Followed by Docetaxel Regimen","longName":"6005263","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AC Followed by Docetaxel Regimen","conceptCode":"C138030","definition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-5103-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD3A3AE-511C-1705-E053-F662850A75D8","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"Vorinostat","valueDescription":"Vorinostat","ValueMeaning":{"publicId":"3380298","version":"1","preferredName":"Vorinostat","longName":"3380298","preferredDefinition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorinostat","conceptCode":"C1796","definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5B1-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8EA5-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Vincristin, Dactinomycin, Cyclophosphamide (VAC)","valueDescription":"Cyclophosphamide/Dactinomycin/Vincristine","ValueMeaning":{"publicId":"6029471","version":"1","preferredName":"Cyclophosphamide/Dactinomycin/Vincristine","longName":"6029471","preferredDefinition":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide, which is used for the treatment of rhabdomyosarcoma (RMS) and ovarian germ cell tumors","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAC Regimen","conceptCode":"C67299","definition":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide that may be used for the treatment of Ewing sarcoma, mesenchymal chondrosarcoma, rhabdomyosarcoma (RMS), malignant sex cord-stromal tumors and malignant germ cell tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-8EB2-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"COOPERM","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8ECB-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Vincristine","valueDescription":"Vincristine","ValueMeaning":{"publicId":"3380295","version":"1","preferredName":"Vincristine","longName":"3380295","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A54A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8EDF-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Trastuzumab","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8EF3-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Topotecan","valueDescription":"Topotecan","ValueMeaning":{"publicId":"3380233","version":"1","preferredName":"Topotecan","longName":"3380233","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1648-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F07-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":"Procarbazine","ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F1B-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F25-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Pirarubicin","valueDescription":"Pirarubicin","ValueMeaning":{"publicId":"6029473","version":"1","preferredName":"Pirarubicin","longName":"6029473","preferredDefinition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pirarubicin","conceptCode":"C1197","definition":"An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-8F32-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F4B-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Panobinostat","valueDescription":"Panobinostat","ValueMeaning":{"publicId":"3379455","version":"1","preferredName":"Panobinostat","longName":"3379455","preferredDefinition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panobinostat","conceptCode":"C66948","definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2334-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F5F-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"5127393","version":"1","preferredName":"Methotrexate","longName":"5127393","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9D7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F73-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Melphalan","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F88-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Lomustine","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8F9C-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Leucovorin","valueDescription":"Leucovorin","ValueMeaning":{"publicId":"6029475","version":"1","preferredName":"Leucovorin","longName":"6029475","preferredDefinition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin","conceptCode":"C71631","definition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-8FA9-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8FC1-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Ifosfamide, Carboplatin, Cisplatin","valueDescription":"Carboplatin/Cisplatin/Ifosfamide","ValueMeaning":{"publicId":"6029477","version":"1","preferredName":"Carboplatin/Cisplatin/Ifosfamide","longName":"6029477","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Cisplatin/Ifosfamide","conceptCode":"C10379","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-8FCF-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-8FE8-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Ifosfamide and Etoposide","valueDescription":"Etoposide/Ifosfamide","ValueMeaning":{"publicId":"6029479","version":"1","preferredName":"Etoposide/Ifosfamide","longName":"6029479","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide/Ifosfamide","conceptCode":"C10182","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-8FF5-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-900E-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-9022-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Dactinomycin","valueDescription":"Dactinomycin","ValueMeaning":{"publicId":"3378914","version":"1","preferredName":"Dactinomycin","longName":"3378914","preferredDefinition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dactinomycin","conceptCode":"C412","definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F71D-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-9036-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine","ValueMeaning":{"publicId":"3270479","version":"1","preferredName":"Cytarabine","longName":"3270479","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67D4-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-904A-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Cis-retinoic acid","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-905E-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Cisplatin, 5-Fluorouracil, Trastuzumab","valueDescription":"Cisplatin/Fluorouracil/Trastuzumab Regimen","ValueMeaning":{"publicId":"6029480","version":"1","preferredName":"Cisplatin/Fluorouracil/Trastuzumab Regimen","longName":"6029480","preferredDefinition":"A regimen consisting of cisplatin, fluorouracil and trastuzumab that can be used in the treatment of gastric cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Fluorouracil/Trastuzumab Regimen","conceptCode":"C141505","definition":"A regimen consisting of cisplatin, fluorouracil and trastuzumab that can be used in the treatment of gastric cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-906A-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-9083-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Carmustine","valueDescription":"Carmustine","ValueMeaning":{"publicId":"3378823","version":"1","preferredName":"Carmustine","longName":"3378823","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-158F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-9097-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-90AB-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Busulfan and Melphalan","valueDescription":"Busulfan/Melphalan","ValueMeaning":{"publicId":"6029482","version":"1","preferredName":"Busulfan/Melphalan","longName":"6029482","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan/Melphalan","conceptCode":"C10133","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-90B8-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-90D1-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Albumin-bound Paclitaxel","valueDescription":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","ValueMeaning":{"publicId":"5567089","version":"1","preferredName":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","longName":"5567089","preferredDefinition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nab-paclitaxel","conceptCode":"C2688","definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC75-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-90E5-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"5-Fluorouracil and Leucovorin","valueDescription":"Infusional Fluorouracil/Leucovorin Regimen","ValueMeaning":{"publicId":"6029484","version":"1","preferredName":"Infusional Fluorouracil/Leucovorin Regimen","longName":"6029484","preferredDefinition":"A chemotherapy regimen consisting of infusional fluorouracil and leucovorin that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil Infusional/Leucovorin Regimen","conceptCode":"C136256","definition":"A chemotherapy regimen consisting of infusional fluorouracil and leucovorin that is used for the treatment of colon cancer and ampullary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1FDBB4-90F2-207B-E053-F662850A7384","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-910B-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"5-Fluorouracil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"5567087","version":"1","preferredName":"Fluorouracil","longName":"5567087","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC2F-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E1FDBB4-9115-207B-E053-F662850A7384","beginDate":"2017-11-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-16","modifiedBy":"ONEDATA","dateModified":"2017-11-16","deletedIndicator":"No"},{"value":"Trifluridine","valueDescription":"Trifluridine","ValueMeaning":{"publicId":"3203290","version":"1","preferredName":"Trifluridine","longName":"3203290","preferredDefinition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trifluridine","conceptCode":"C905","definition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8654C5-9B06-1C49-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64028F52-DA11-69E8-E053-F662850AAE65","beginDate":"2018-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"Lapatinib","valueDescription":"Lapatinib","ValueMeaning":{"publicId":"4916291","version":"1","preferredName":"Lapatinib","longName":"4916291","preferredDefinition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-8FEE-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64028F52-DA1B-69E8-E053-F662850AAE65","beginDate":"2018-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"Neratinib","valueDescription":"Neratinib","ValueMeaning":{"publicId":"3720773","version":"1","preferredName":"Neratinib","longName":"3720773","preferredDefinition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neratinib","conceptCode":"C49094","definition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA06151A-148F-0504-E040-BB89AD437F71","latestVersionIndicator":"Yes","beginDate":"2013-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64028F52-DA25-69E8-E053-F662850AAE65","beginDate":"2018-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-30","modifiedBy":"ONEDATA","dateModified":"2018-01-30","deletedIndicator":"No"},{"value":"Carboplatin and Pemetrexed","valueDescription":"Carboplatin And Pemetrexed","ValueMeaning":{"publicId":"5810425","version":"1","preferredName":"Carboplatin And Pemetrexed","longName":"5810425","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F028705-9225-55C2-E053-F662850A0575","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"63787F4F-8333-7D3A-E053-F662850AE8C5","beginDate":"2018-01-23","endDate":null,"createdBy":"PATELV","dateCreated":"2018-01-23","modifiedBy":"ONEDATA","dateModified":"2018-01-23","deletedIndicator":"No"},{"value":"Vincristine, actinomycin-D, cyclophosphamide, vincristine, irinotecan (VAC/VI)","valueDescription":"VAC/VI Regimen","ValueMeaning":{"publicId":"6183609","version":"1","preferredName":"VAC/VI Regimen","longName":"6183609","preferredDefinition":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide, alternating with vincristine and irinotecan that can be used for the treatment of rhabdomyosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAC Alternating with VI Regimen","conceptCode":"C148284","definition":"A regimen consisting of vincristine, dactinomycin and cyclophosphamide, alternating with vincristine and irinotecan that can be used for the treatment of rhabdomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69938338-6388-4320-E053-F662850A441C","latestVersionIndicator":"Yes","beginDate":"2018-04-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69938338-63A1-4320-E053-F662850A441C","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","deletedIndicator":"No"},{"value":"Vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide (VDC/IE)","valueDescription":"VAdriaC-IE Regimen","ValueMeaning":{"publicId":"6183610","version":"1","preferredName":"VAdriaC-IE Regimen","longName":"6183610","preferredDefinition":"A regimen consisting of vincristine, doxorubicin and cyclophosphamide, alternating with ifosfamide and etoposide that can be used for the treatment of Ewing sarcoma and mesenchymal chondrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAdriaC Alternating with IE Regimen","conceptCode":"C67232","definition":"A regimen consisting of vincristine, doxorubicin and cyclophosphamide, alternating with ifosfamide and etoposide that can be used for the treatment of Ewing sarcoma, nonpleomorphic rhabdomyosarcoma and mesenchymal chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69938338-63AD-4320-E053-F662850A441C","latestVersionIndicator":"Yes","beginDate":"2018-04-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69938338-63C6-4320-E053-F662850A441C","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","deletedIndicator":"No"},{"value":"Vincristine, irinotecan, temozolomide (VIT)","valueDescription":"VIT Regimen","ValueMeaning":{"publicId":"6183611","version":"1","preferredName":"VIT Regimen","longName":"6183611","preferredDefinition":"A regimen consisting of vincristine, irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIT Regimen","conceptCode":"C148285","definition":"A regimen consisting of vincristine, irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma and nonpleomorphic rhabdomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69938338-63D2-4320-E053-F662850A441C","latestVersionIndicator":"Yes","beginDate":"2018-04-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69938338-63EB-4320-E053-F662850A441C","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-11","modifiedBy":"ONEDATA","dateModified":"2018-04-11","deletedIndicator":"No"},{"value":"High-dose methotrexate, doxorubicin, cisplatin (MAP)","valueDescription":"Cisplatin-Doxorubicin-Methotrexate Regimen","ValueMeaning":{"publicId":"6161739","version":"1","preferredName":"Cisplatin-Doxorubicin-Methotrexate Regimen","longName":"6161739","preferredDefinition":"A regimen consisting of cisplatin, doxorubicin, and methotrexate used as an adjuvant treatment for localized childhood osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP Regimen","conceptCode":"C67339","definition":"A regimen consisting of cisplatin, doxorubicin, and methotrexate that can be used in the treatment of osteosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F533A-F89B-5967-E053-F662850A365F","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-05","modifiedBy":"COOPERM","dateModified":"2018-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F533A-F8B4-5967-E053-F662850A365F","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"Ifosfamide, carboplatin, etoposide (ICE)","valueDescription":"ICE Regimen","ValueMeaning":{"publicId":"3366711","version":"1","preferredName":"ICE Regimen","longName":"3366711","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5264-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F533A-F8EB-5967-E053-F662850A365F","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"Alectinib","valueDescription":"Alectinib","ValueMeaning":{"publicId":"4828189","version":"1","preferredName":"Alectinib","longName":"4828189","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alectinib","conceptCode":"C101790","definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49DD-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66EA6EE2-D486-1BC0-E053-F662850AA277","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"Ensartinib","valueDescription":"Ensartinib","ValueMeaning":{"publicId":"6054163","version":"1","preferredName":"Ensartinib","longName":"6054163","preferredDefinition":"784729-Ensartinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E1FB-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66EA6EE2-D49A-1BC0-E053-F662850AA277","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"Brigatinib","valueDescription":"Brigatinib","ValueMeaning":{"publicId":"6117828","version":"1","preferredName":"Brigatinib","longName":"6117828","preferredDefinition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brigatinib","conceptCode":"C98831","definition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EA6EE2-D4A8-1BC0-E053-F662850AA277","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66EA6EE2-D4C1-1BC0-E053-F662850AA277","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"Lorlatinib","valueDescription":"Lorlatinib","ValueMeaning":{"publicId":"6117830","version":"1","preferredName":"Lorlatinib","longName":"6117830","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorlatinib","conceptCode":"C113655","definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EA6EE2-D4CE-1BC0-E053-F662850AA277","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66EA6EE2-D4E7-1BC0-E053-F662850AA277","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"GEMOX (Gemcitabine, Oxaliplatin)","valueDescription":"Gemcitabine-Oxaliplatin Regimen","ValueMeaning":{"publicId":"6002932","version":"1","preferredName":"Gemcitabine-Oxaliplatin Regimen","longName":"6002932","preferredDefinition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GemOx Regimen","conceptCode":"C64833","definition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F1B-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7407B4EA-94CA-1FD8-E053-F662850ABDCB","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"TS-1","valueDescription":"Tegafur-gimeracil-oteracil Potassium","ValueMeaning":{"publicId":"6159923","version":"1","preferredName":"Tegafur-gimeracil-oteracil Potassium","longName":"6159923","preferredDefinition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tegafur-gimeracil-oteracil Potassium","conceptCode":"C1833","definition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-1447-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7407B4EA-94DF-1FD8-E053-F662850ABDCB","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Ipilimumab and Nivolumab","valueDescription":"Ipilimumab and Nivolumab Regimen","ValueMeaning":{"publicId":"6409150","version":"1","preferredName":"Ipilimumab and Nivolumab Regimen","longName":"6409150","preferredDefinition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab/Nivolumab Regimen","conceptCode":"C154272","definition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone cancer, kidney cancer, colorectal cancer, melanoma, non-small cell lung cancer (NSCLC), and malignant pleural/peritoneal mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-661C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"SOKKERL","dateModified":"2019-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-6635-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-663F-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Encorafenib and Binimetinib","valueDescription":"Encorafenib and Binimetinib Regimen","ValueMeaning":{"publicId":"6409151","version":"1","preferredName":"Encorafenib and Binimetinib Regimen","longName":"6409151","preferredDefinition":"A regimen consisting of encorafenib and binimetinib that can be used for the treatment of melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Binimetinib/Encorafenib Regimen","conceptCode":"C154326","definition":"A regimen consisting of binimetinib and encorafenib that can be used for the treatment of melanoma and non-small cell lung cancer (NSCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-6649-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"COOPERM","dateModified":"2018-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-6662-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Dabrafenib and Trametinib","valueDescription":"Dabrafenib and Trametinib Regimen","ValueMeaning":{"publicId":"6409152","version":"1","preferredName":"Dabrafenib and Trametinib Regimen","longName":"6409152","preferredDefinition":"A regimen consisting of dabrafenib and trametinib that can be used for the treatment of melanoma, NSCLC, and thyroid cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib/Trametinib Regimen","conceptCode":"C154325","definition":"A regimen consisting of dabrafenib and trametinib that can be used in the treatment of certain BRAF-mutated cutaneous melanomas, non-small cell lung cancers (NSCLCs), anaplastic carcinoma, central nervous system (CNS) cancers, gastric, esophageal and esophagogastric junction cancers, salivary gland tumors, oncocytic carcinoma, ovarian, fallopian tube and primary peritoneal cancers, follicular, papillary and Hurthle cell thyroid carcinomas, ampullary, pancreatic and small bowel adenocarcinoma, gallbladder or cholangiocarcinoma, gastrointestinal stromal tumor (GIST), occult primary adenocarcinoma or squamous cell carcinoma, extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, and mixed neuroendocrine-non-neuroendocrine neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-666C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"COOPERM","dateModified":"2018-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-6685-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Vemurafenib and Cobimetinib","valueDescription":"Vemurafenib and Cobimetinib Regimen","ValueMeaning":{"publicId":"6409153","version":"1","preferredName":"Vemurafenib and Cobimetinib Regimen","longName":"6409153","preferredDefinition":"A regimen consisting of vemurafenib and cobimetinib that can be used for the treatment of melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobimetinib/Vemurafenib Regimen","conceptCode":"C154327","definition":"A regimen consisting of vemurafenib and cobimetinib that can be used for the treatment of melanoma and central nervous system (CNS) cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-668F-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"COOPERM","dateModified":"2018-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-66A8-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-66B2-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7409E9E8-66BC-4EFE-E053-F662850A32CC","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","deletedIndicator":"No"},{"value":"Altretamine","valueDescription":"Hexamethylmelamine (Altretamine)","ValueMeaning":{"publicId":"2576918","version":"1","preferredName":"Hexamethylmelamine (Altretamine)","longName":"2576918","preferredDefinition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Altretamine","conceptCode":"C544","definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F983-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869CB3AF-7655-4D5B-E053-F662850A2A84","beginDate":"2019-04-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"MEK Inhibitor","valueDescription":"Mitogen-Activated Protein Kinase Kinase Inhibitor","ValueMeaning":{"publicId":"3218952","version":"1","preferredName":"Mitogen-Activated Protein Kinase Kinase Inhibitor","longName":"3218952","preferredDefinition":"Substances that inhibit Mitogen-Activated Protein Kinase Kinase (MEK), enzymes involved with signal transduction, and may inhibit cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitogen-Activated Protein Kinase Kinase Inhibitor","conceptCode":"C69145","definition":"Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen-activated protein kinase. Inhibition of mitogen-activated protein kinase kinase results in the inhibition of cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FCB1285-74AB-D8CA-E040-BB89AD433739","latestVersionIndicator":"Yes","beginDate":"2011-03-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848B0602-EF97-6BF2-E053-F662850A9E58","beginDate":"2019-03-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"BRAF Inhibitor","valueDescription":"BRAF Inhibitor","ValueMeaning":{"publicId":"6678120","version":"1","preferredName":"BRAF Inhibitor","longName":"6678120","preferredDefinition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF Inhibitor","conceptCode":"C155322","definition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848B0602-EFA5-6BF2-E053-F662850A9E58","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848B0602-EFBE-6BF2-E053-F662850A9E58","beginDate":"2019-03-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"Carboplatin, Paclitaxel, and Cetuximab","valueDescription":"PCC Regimen","ValueMeaning":{"publicId":"6785190","version":"1","preferredName":"PCC Regimen","longName":"6785190","preferredDefinition":"A chemoimmunotherapy regimen consisting of paclitaxel, carboplatin, and cetuximab that can be used for the treatment of squamous cell carcinoma of the head and neck (SCCHN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PCC Regimen","conceptCode":"C37597","definition":"A regimen consisting of paclitaxel, carboplatin, and cetuximab that can be used for the treatment of squamous cell carcinoma of the head and neck (SCCHN).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0C395-CB55-27CD-E053-F662850A4BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDAE508-6F05-0286-E053-F662850AD6BB","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"Androgen deprivation therapy (ADT)","valueDescription":"Antiandrogen Therapy","ValueMeaning":{"publicId":"5053421","version":"1","preferredName":"Antiandrogen Therapy","longName":"5053421","preferredDefinition":"Treatment with drugs used to block production or interfere with the action of male sex hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiandrogen Therapy","conceptCode":"C15481","definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"253EB018-6267-7E8E-E050-BB89AD43347B","latestVersionIndicator":"Yes","beginDate":"2015-11-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D458107-9859-48DF-E053-F662850AB5FF","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Decadron (dexamethasone)","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D458107-986D-48DF-E053-F662850AB5FF","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Cabazitaxel","valueDescription":"Cabazitaxel Regimen","ValueMeaning":{"publicId":"6814251","version":"1","preferredName":"Cabazitaxel Regimen","longName":"6814251","preferredDefinition":"A regimen consisting of cabizitaxel that may be used in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabazitaxel Regimen","conceptCode":"C160797","definition":"A regimen consisting of cabizitaxel that may be used in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D458107-987A-48DF-E053-F662850AB5FF","latestVersionIndicator":"Yes","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D458107-9893-48DF-E053-F662850AB5FF","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"Etoposide and carboplatin","valueDescription":"EP Regimen","ValueMeaning":{"publicId":"6814253","version":"1","preferredName":"EP Regimen","longName":"6814253","preferredDefinition":"A regimen consisting of etoposide and cisplatin that can be used in the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and testicular cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EP Regimen","conceptCode":"C63382","definition":"A regimen consisting of etoposide and cisplatin that can be used in the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and testicular cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D458107-98A0-48DF-E053-F662850AB5FF","latestVersionIndicator":"Yes","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D458107-98B9-48DF-E053-F662850AB5FF","beginDate":"2019-07-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-09","modifiedBy":"ONEDATA","dateModified":"2019-07-09","deletedIndicator":"No"},{"value":"mFOLFOX6","valueDescription":"Modified FOLFOX6 Regimen","ValueMeaning":{"publicId":"6819078","version":"1","preferredName":"Modified FOLFOX6 Regimen","longName":"6819078","preferredDefinition":"A chemotherapy regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of advanced-stage and metastatic colorectal cancer. This modified version differs from the FOLFOX6 regimen in that the dose of oxaliplatin is lower.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified FOLFOX6 Regimen","conceptCode":"C155746","definition":"A chemotherapy regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of advanced-stage and metastatic colorectal cancer. This modified version differs from the FOLFOX6 regimen in that the dose of oxaliplatin is lower.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DCBD5BA-CB56-5372-E053-F662850A10D5","latestVersionIndicator":"Yes","beginDate":"2019-07-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-16","modifiedBy":"ONEDATA","dateModified":"2019-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DCBD5BA-CB6F-5372-E053-F662850A10D5","beginDate":"2019-07-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-16","modifiedBy":"ONEDATA","dateModified":"2019-07-16","deletedIndicator":"No"},{"value":"FOLFOX + cetuximab","valueDescription":"FOLFOX/Cetuximab Regimen","ValueMeaning":{"publicId":"6847076","version":"1","preferredName":"FOLFOX/Cetuximab Regimen","longName":"6847076","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus cetuximab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX-Cetuximab Regimen","conceptCode":"C136246","definition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus cetuximab that is used for the treatment of colon cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D30F-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D328-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"FOLFOX + panitumumab","valueDescription":"FOLFOX/Panitumumab Regimen","ValueMeaning":{"publicId":"6847078","version":"1","preferredName":"FOLFOX/Panitumumab Regimen","longName":"6847078","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus panitumumab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX-Panitumumab Regimen","conceptCode":"C136247","definition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus panitumumab that is used for the treatment of colon cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D335-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D34E-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"FOLFIRI + cetuximab","valueDescription":"FOLFIRI-Cetuximab Regimen","ValueMeaning":{"publicId":"6847080","version":"1","preferredName":"FOLFIRI-Cetuximab Regimen","longName":"6847080","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin (folinic acid), 5-fluorouracil, and irinotecan plus cetuximab used for the treatment of metastatic colorectal cancer that is positive for the expression of the epidermal growth factor receptor (EGFR) and the wild-type form of KRAS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFIRI-Cetuximab Regimen","conceptCode":"C104152","definition":"A regimen consisting of leucovorin (folinic acid), 5-fluorouracil, and irinotecan plus cetuximab that can be used for the treatment of colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D35B-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D374-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"FOLFIRI + panitumumab","valueDescription":"FOLFIRI/Panitumumab Regimen","ValueMeaning":{"publicId":"6847082","version":"1","preferredName":"FOLFIRI/Panitumumab Regimen","longName":"6847082","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus panitumumab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFIRI-Panitumumab Regimen","conceptCode":"C136249","definition":"A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus panitumumab that is used for the treatment of colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D381-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D39A-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"FOLFIRI + bevacizumab","valueDescription":"FOLFIRI-Bevacizumab Regimen","ValueMeaning":{"publicId":"6847084","version":"1","preferredName":"FOLFIRI-Bevacizumab Regimen","longName":"6847084","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil, irinotecan and bevacizumab used for as an initial treatment for advanced-stage metastatic colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFIRI-Bevacizumab Regimen","conceptCode":"C63608","definition":"A regimen consisting of bevacizumab, fluorouracil, irinotecan and leucovorin that may be used in the treatment of ampullary and appendiceal adenocarcinoma, colorectal cancer, and small bowel adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D3A7-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D3C0-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"CAPEOX","valueDescription":"CAPOX Regimen","ValueMeaning":{"publicId":"6847085","version":"1","preferredName":"CAPOX Regimen","longName":"6847085","preferredDefinition":"A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAPOX Regimen","conceptCode":"C63596","definition":"A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D3CC-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D3E5-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"CAPEOX (CAPOX) + bevacizumab","valueDescription":"CAPOX-Bevacizumab Regimen","ValueMeaning":{"publicId":"6847087","version":"1","preferredName":"CAPOX-Bevacizumab Regimen","longName":"6847087","preferredDefinition":"A chemoimmunotherapy regimen consisting of capecitabine, oxaliplatin and bevacizumab used as an initial treatment for advanced-stage or metastatic colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAPOX-Bevacizumab Regimen","conceptCode":"C63609","definition":"A regimen consisting of bevacizumab, capecitabine and oxaliplatin that may be used in the treatment of colorectal cancer, small bowel, appendiceal, and ampullary adenocarcinoma and mucinous carcinoma of the ovary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D3F2-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D40B-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"5-FU/LV + cetuximab","valueDescription":"FU-LV Regimen Cetuximab Regimen","ValueMeaning":{"publicId":"6847089","version":"1","preferredName":"FU-LV Regimen Cetuximab Regimen","longName":"6847089","preferredDefinition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.: An immunotherapy regimen consisting of cetuximab that may be used in the treatment of colorectal, penile, and head and neck cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FU-LV Regimen","conceptCode":"C63388","definition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cetuximab Regimen","conceptCode":"C160009","definition":"An immunotherapy regimen consisting of cetuximab that may be used in the treatment of colorectal, penile, and head and neck cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D419-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D432-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"5-FU/LV + panitumumab","valueDescription":"FU-LV Regimen Panitumumab Regimen","ValueMeaning":{"publicId":"6847091","version":"1","preferredName":"FU-LV Regimen Panitumumab Regimen","longName":"6847091","preferredDefinition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.: An immunotherapy regimen consisting of panitumumab that may be used in the treatment of wild-type RAS metastatic colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FU-LV Regimen","conceptCode":"C63388","definition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Panitumumab Regimen","conceptCode":"C160104","definition":"A regimen consisting of panitumumab that may be used in the treatment of wild-type RAS metastatic colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D440-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D459-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"5-FU/LV","valueDescription":"FU-LV Regimen","ValueMeaning":{"publicId":"3378086","version":"1","preferredName":"FU-LV Regimen","longName":"3378086","preferredDefinition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FU-LV Regimen","conceptCode":"C63388","definition":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-351C-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F717997-D46D-1812-E053-F662850A6D71","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","deletedIndicator":"No"},{"value":"DA-EPOCH-R","valueDescription":"R-DA-EPOCH  Regimen","ValueMeaning":{"publicId":"6002924","version":"1","preferredName":"R-DA-EPOCH  Regimen","longName":"6002924","preferredDefinition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose-adjusted EPOCH-R Regimen","conceptCode":"C140097","definition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of AIDS-related B-cell lymphomas, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7ECD-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AA4B087-B2CF-3E45-E053-F662850AFA42","beginDate":"2019-06-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-06","modifiedBy":"ONEDATA","dateModified":"2019-06-06","deletedIndicator":"No"},{"value":"Per AALL1331 Arm C","valueDescription":"Per AALL1331 Arm C","ValueMeaning":{"publicId":"6835244","version":"1","preferredName":"Per AALL1331 Arm C","longName":"6835244","preferredDefinition":"Per AALL1331 Arm C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-736E-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-7387-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Per AALL1331 Arm A","valueDescription":"Per AALL1331 Arm A","ValueMeaning":{"publicId":"6835245","version":"1","preferredName":"Per AALL1331 Arm A","longName":"6835245","preferredDefinition":"Per AALL1331 Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8ED57FE4-7391-297C-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2019-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED57FE4-73AA-297C-E053-F662850AE546","beginDate":"2019-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Gemcitabine and Paclitaxel","valueDescription":"Gemcitabine/Paclitaxel","ValueMeaning":{"publicId":"6785185","version":"1","preferredName":"Gemcitabine/Paclitaxel","longName":"6785185","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine/Paclitaxel","conceptCode":"C11430","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0C395-CAD0-27CD-E053-F662850A4BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BA0C395-CAE9-27CD-E053-F662850A4BF9","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","deletedIndicator":"No"},{"value":"Cisplatin (Carboplatin) and Paclitaxel","valueDescription":"Carboplatin/Paclitaxel","ValueMeaning":{"publicId":"3378370","version":"1","preferredName":"Carboplatin/Paclitaxel","longName":"3378370","preferredDefinition":"Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Paclitaxel","conceptCode":"C10662","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B905A965-2E93-08AF-E040-BB89AD430955","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BA0C395-CAFD-27CD-E053-F662850A4BF9","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","deletedIndicator":"No"},{"value":"Carboplatin (Cisplatin), Fluorouracil, and Pembrolizumab","valueDescription":"Carboplatin/Fluorouracil/Pembrolizumab Regimen","ValueMeaning":{"publicId":"6785186","version":"1","preferredName":"Carboplatin/Fluorouracil/Pembrolizumab Regimen","longName":"6785186","preferredDefinition":"A regimen consisting of carboplatin, fluorouracil (5-FU) and pembrolizumab that may be used in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Fluorouracil/Pembrolizumab Regimen","conceptCode":"C160959","definition":"A regimen consisting of carboplatin, fluorouracil (5-FU) and pembrolizumab that may be used in the treatment of head and neck cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0C395-CB09-27CD-E053-F662850A4BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BA0C395-CB22-27CD-E053-F662850A4BF9","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","deletedIndicator":"No"},{"value":"Cisplatin, Paclitaxel, and Cetuximab","valueDescription":"Cisplatin/Paclitaxel/Cetuximab Regimen","ValueMeaning":{"publicId":"6785188","version":"1","preferredName":"Cisplatin/Paclitaxel/Cetuximab Regimen","longName":"6785188","preferredDefinition":"A chemoimmunotherapy regimen consisting of cisplatin, paclitaxel and cetuximab that can be used for the treatment of head and neck cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Paclitaxel/Cetuximab Regimen","conceptCode":"C150693","definition":"A chemoimmunotherapy regimen consisting of cisplatin, paclitaxel and cetuximab that can be used for the treatment of head and neck cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0C395-CB2F-27CD-E053-F662850A4BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BA0C395-CB48-27CD-E053-F662850A4BF9","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","deletedIndicator":"No"},{"value":"Docetaxel, Carboplatin, and Fluorouracil","valueDescription":"TCF Regimen","ValueMeaning":{"publicId":"6785191","version":"1","preferredName":"TCF Regimen","longName":"6785191","preferredDefinition":"A chemotherapy regimen consisting of carboplatin, docetaxel and 5-fluorouracil that can be used in the treatment of advanced head and neck, gastric and cervical cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCF Regimen","conceptCode":"C160553","definition":"A regimen consisting of carboplatin, docetaxel and 5-fluorouracil that can be used in the treatment of gastric, cervical, head and neck, and esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BA0C395-CB7A-27CD-E053-F662850A4BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BA0C395-CB93-27CD-E053-F662850A4BF9","beginDate":"2019-06-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-18","modifiedBy":"ONEDATA","dateModified":"2019-06-18","deletedIndicator":"No"},{"value":"Goserelin Acetate","valueDescription":"Goserelin Acetate","ValueMeaning":{"publicId":"3380783","version":"1","preferredName":"Goserelin Acetate","longName":"3380783","preferredDefinition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin Acetate","conceptCode":"C1417","definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B54-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8747E9C6-D0AD-4FF9-E053-F662850A0798","beginDate":"2019-04-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"Sunitinib","valueDescription":"Sunitinib","ValueMeaning":{"publicId":"3107588","version":"1","preferredName":"Sunitinib","longName":"3107588","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-10C5-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDD488F-64AC-7D47-E053-F662850AFAC9","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"5-FU/LV + bevacizumab","valueDescription":"FU-LV-Bevacizumab Regimen","ValueMeaning":{"publicId":"6846441","version":"1","preferredName":"FU-LV-Bevacizumab Regimen","longName":"6846441","preferredDefinition":"A chemo-immunotherapy regimen consisting of fluorouracil, leucovorin, and bevacizumab used for the treatment of advanced-stage colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FU-LV-Bevacizumab Regimen","conceptCode":"C63610","definition":"A chemo-immunotherapy regimen consisting of fluorouracil, leucovorin, and bevacizumab used for the treatment of advanced-stage colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-916F-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-9188-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Irinotecan + bevacizumab","valueDescription":"Irinotecan/Bevacizumab Regimen","ValueMeaning":{"publicId":"6846443","version":"1","preferredName":"Irinotecan/Bevacizumab Regimen","longName":"6846443","preferredDefinition":"A chemoimmunotherapy regimen consisting of irinotecan and bevacizumab that is used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab/Irinotecan Regimen","conceptCode":"C136258","definition":"A regimen consisting of irinotecan and bevacizumab that can be used for the treatment of colorectal cancer and appendiceal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-9195-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-91AE-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Irinotecan + cetuximab","valueDescription":"Irinotecan-Cetuximab Regimen","ValueMeaning":{"publicId":"6846445","version":"1","preferredName":"Irinotecan-Cetuximab Regimen","longName":"6846445","preferredDefinition":"A chemo-immunotherapy regimen consisting of irinotecan and cetuximab used for the treatment of advanced stage colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab/Irinotecan Regimen","conceptCode":"C63606","definition":"A regimen consisting of irinotecan and cetuximab that can be used for the treatment of colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-91BB-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-91D4-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Irinotecan + panitumumab","valueDescription":"Irinotecan/Panitumumab Regimen","ValueMeaning":{"publicId":"6846447","version":"1","preferredName":"Irinotecan/Panitumumab Regimen","longName":"6846447","preferredDefinition":"A chemoimmunotherapy regimen consisting of irinotecan and panitumumab that can be used for the treatment of colon cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan/Panitumumab Regimen","conceptCode":"C153481","definition":"A regimen consisting of irinotecan and panitumumab that can be used for the treatment of colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-91E1-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-91FA-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-9204-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Panitumumab","valueDescription":"Panitumumab","ValueMeaning":{"publicId":"3379440","version":"1","preferredName":"Panitumumab","longName":"3379440","preferredDefinition":"A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panitumumab","conceptCode":"C1857","definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2183-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-920E-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Trifluridine/tiptracil","valueDescription":"Trifluridine and Tipiracil Regimen","ValueMeaning":{"publicId":"6846449","version":"1","preferredName":"Trifluridine and Tipiracil Regimen","longName":"6846449","preferredDefinition":"A chemotherapy regimen consisting of trifluridine and tipiracil that may be used in the treatment of metastatic colorectal cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tipiracil/Trifluridine Regimen","conceptCode":"C160136","definition":"A regimen consisting of tipiracil and trifluridine that may be used in the treatment of appendiceal adenocarcinoma, esophageal and esophagogastric junction and gastric cancers, and metastatic colorectal cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-921B-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-9234-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Regorafenib","valueDescription":"Regorafenib","ValueMeaning":{"publicId":"3729312","version":"1","preferredName":"Regorafenib","longName":"3729312","preferredDefinition":"An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regorafenib","conceptCode":"C78204","definition":"The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0A510A-06A5-547A-E040-BB89AD436C02","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-923E-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-9248-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"Nivolumab + ipilumimab","valueDescription":"Ipilimumab and Nivolumab Regimen","ValueMeaning":{"publicId":"6409150","version":"1","preferredName":"Ipilimumab and Nivolumab Regimen","longName":"6409150","preferredDefinition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab/Nivolumab Regimen","conceptCode":"C154272","definition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone cancer, kidney cancer, colorectal cancer, melanoma, non-small cell lung cancer (NSCLC), and malignant pleural/peritoneal mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-661C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"SOKKERL","dateModified":"2019-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F63A637-925C-69C7-E053-F662850AD19F","beginDate":"2019-08-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","deletedIndicator":"No"},{"value":"R-CHOP","valueDescription":"R-CHOP Regimen","ValueMeaning":{"publicId":"6002915","version":"1","preferredName":"R-CHOP Regimen","longName":"6002915","preferredDefinition":"An immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOP Regimen","conceptCode":"C9760","definition":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenstrm macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E226-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A97A4B5-EC5A-740D-E053-F662850A8156","beginDate":"2019-06-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-05","modifiedBy":"ONEDATA","dateModified":"2019-06-05","deletedIndicator":"No"},{"value":"CAPOX","valueDescription":"Oxaliplatin Capecitabine","ValueMeaning":{"publicId":"7060634","version":"1","preferredName":"Oxaliplatin Capecitabine","longName":"7060634","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04): A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A08FB4-B50A-543C-E053-F662850AD86C","latestVersionIndicator":"Yes","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A08FB4-B523-543C-E053-F662850AD86C","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","deletedIndicator":"No"},{"value":"Carboplatin (Cisplatin), Fluouracil and Cetuximab","valueDescription":"Carboplatin/Fluorouracil/Cetuximab Regimen Or Cisplatin/Fluorouracil/Cetuximab Regimen","ValueMeaning":{"publicId":"6978644","version":"1","preferredName":"Carboplatin/Fluorouracil/Cetuximab Regimen Or Cisplatin/Fluorouracil/Cetuximab Regimen","longName":"6978644","preferredDefinition":"A chemoimmunotherapy regimen consisting of carboplatin, fluorouracil (5-FU) and cetuximab that can be used for the treatment of head and neck cancer.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A chemoimmunotherapy regimen consisting of cisplatin, fluorouracil (5-FU) and cetuximab used for the treatment of various types of head and neck cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin/Cetuximab/Fluorouracil Regimen","conceptCode":"C150686","definition":"A chemoimmunotherapy regimen consisting of carboplatin, fluorouracil (5-FU) and cetuximab that can be used for the treatment of head and neck cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cetuximab/Cisplatin/Fluorouracil Regimen","conceptCode":"C150691","definition":"A chemoimmunotherapy regimen consisting of cisplatin, fluorouracil (5-FU) and cetuximab used for the treatment of various types of head and neck cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94959232-A279-083E-E053-F662850AE645","latestVersionIndicator":"Yes","beginDate":"2019-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94959232-A292-083E-E053-F662850AE645","beginDate":"2019-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-10","modifiedBy":"ONEDATA","dateModified":"2019-10-10","deletedIndicator":"No"},{"value":"Docetaxel and Capecitabine","valueDescription":"Docetaxel and Capecitabine","ValueMeaning":{"publicId":"7372476","version":"1","preferredName":"Docetaxel and Capecitabine","longName":"7372476","preferredDefinition":"Docetaxel and Capecitabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8661D6-0D6D-6AA2-E053-4EBD850A6DE2","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"PATELV","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB8661D6-0D86-6AA2-E053-4EBD850A6DE2","beginDate":"2020-07-28","endDate":null,"createdBy":"PATELV","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Docetaxel and 5FU","valueDescription":"Docetaxel and 5-Fluorouracil","ValueMeaning":{"publicId":"7372477","version":"1","preferredName":"Docetaxel and 5-Fluorouracil","longName":"7372477","preferredDefinition":"Docetaxel and 5-Fluorouracil","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8661D6-0D90-6AA2-E053-4EBD850A6DE2","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"PATELV","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB8661D6-0DA9-6AA2-E053-4EBD850A6DE2","beginDate":"2020-07-28","endDate":null,"createdBy":"PATELV","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Oxaliplatin based","valueDescription":"Base Oxaliplatin","ValueMeaning":{"publicId":"7490634","version":"1","preferredName":"Base Oxaliplatin","longName":"7490634","preferredDefinition":"The most important or necessary part of something.: An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Base","conceptCode":"C48055","definition":"The most important or necessary part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34E4F81-9E3A-5122-E053-4EBD850A70F2","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34E4F81-9E53-5122-E053-4EBD850A70F2","beginDate":"2020-11-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"CPX-351","valueDescription":"Liposome-encapsulated Daunorubicin-Cytarabine","ValueMeaning":{"publicId":"7154914","version":"1","preferredName":"Liposome-encapsulated Daunorubicin-Cytarabine","longName":"7154914","preferredDefinition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposome-encapsulated Daunorubicin-Cytarabine","conceptCode":"C67504","definition":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D392C92-8BDA-5364-E053-F662850ABFD8","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-28","modifiedBy":"COLBERTM","dateModified":"2023-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A9984A-7B10-7316-E053-4EBD850AA332","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"Fludarabine (30mg/m2/dose for 5 days) and Cytarabine (2000mg/m2/day for 5 days)","valueDescription":"Fludarabine (30mg/m2/dose for 5 days) and Cytarabine (2000mg/m2/day for 5 days)","ValueMeaning":{"publicId":"7640815","version":"1","preferredName":"Fludarabine (30mg/m2/dose for 5 days) and Cytarabine (2000mg/m2/day for 5 days)","longName":"7640815","preferredDefinition":"Fludarabine (30mg/m2/dose for 5 days) and Cytarabine (2000mg/m2/day for 5 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A9984A-7B1A-7316-E053-4EBD850AA332","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0A9984A-7B33-7316-E053-4EBD850AA332","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"Raltitrexed","valueDescription":"Raltitrexed","ValueMeaning":{"publicId":"3378925","version":"1","preferredName":"Raltitrexed","longName":"3378925","preferredDefinition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltitrexed","conceptCode":"C1804","definition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2C18-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCB86B53-0820-34D1-E053-4EBD850A7197","beginDate":"2021-03-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-04","modifiedBy":"ONEDATA","dateModified":"2021-03-04","deletedIndicator":"No"},{"value":"Navelbine","valueDescription":"Vinorelbine Tartrate","ValueMeaning":{"publicId":"7590019","version":"1","preferredName":"Vinorelbine Tartrate","longName":"7590019","preferredDefinition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine Tartrate","conceptCode":"C1395","definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB86B53-082A-34D1-E053-4EBD850A7197","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-04","modifiedBy":"ONEDATA","dateModified":"2021-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCB86B53-0843-34D1-E053-4EBD850A7197","beginDate":"2021-03-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-04","modifiedBy":"ONEDATA","dateModified":"2021-03-04","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BE1126-6543-5119-E053-4EBD850ADC53","beginDate":"2021-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-05-07","modifiedBy":"ONEDATA","dateModified":"2021-05-07","deletedIndicator":"No"},{"value":"Idarubicin","valueDescription":"Idarubicin","ValueMeaning":{"publicId":"2744955","version":"1","preferredName":"Idarubicin","longName":"2744955","preferredDefinition":"A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin","conceptCode":"C562","definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80C8-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BE1126-654D-5119-E053-4EBD850ADC53","beginDate":"2021-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-05-07","modifiedBy":"ONEDATA","dateModified":"2021-05-07","deletedIndicator":"No"},{"value":"Gemtuzumab","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BE1126-6557-5119-E053-4EBD850ADC53","beginDate":"2021-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-05-07","modifiedBy":"ONEDATA","dateModified":"2021-05-07","deletedIndicator":"No"},{"value":"Mitomycin-C / Capecitabine","valueDescription":"Capecitabine Mitomycin","ValueMeaning":{"publicId":"7715798","version":"1","preferredName":"Capecitabine Mitomycin","longName":"7715798","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04): A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5ECCB19-4C97-35A4-E053-4EBD850A0986","latestVersionIndicator":"Yes","beginDate":"2021-06-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-06-29","modifiedBy":"ONEDATA","dateModified":"2021-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5ECCB19-4CB0-35A4-E053-4EBD850A0986","beginDate":"2021-06-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-06-29","modifiedBy":"ONEDATA","dateModified":"2021-06-29","deletedIndicator":"No"},{"value":"Early discontinuation of immunosuppression","valueDescription":"Early discontinuation of immunosuppression","ValueMeaning":{"publicId":"7122460","version":"1","preferredName":"Early discontinuation of immunosuppression","longName":"7122460","preferredDefinition":"Early discontinuation of immunosuppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D4A8-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB11FDFC-C454-43B9-E053-4EBD850A3C74","beginDate":"2022-03-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-03-25","modifiedBy":"ONEDATA","dateModified":"2022-03-25","deletedIndicator":"No"},{"value":"Donor lymphocyte infusion","valueDescription":"Donor lymphocyte infusion","ValueMeaning":{"publicId":"7122461","version":"1","preferredName":"Donor lymphocyte infusion","longName":"7122461","preferredDefinition":"Donor lymphocyte infusion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B906005-D4CB-21D6-E053-F662850A0C9E","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"LEEW","dateCreated":"2020-01-07","modifiedBy":"ONEDATA","dateModified":"2020-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB11FDFC-C45E-43B9-E053-4EBD850A3C74","beginDate":"2022-03-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-03-25","modifiedBy":"ONEDATA","dateModified":"2022-03-25","deletedIndicator":"No"},{"value":"Tyrosine Kinase Inhibitor","valueDescription":"Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"5127433","version":"1","preferredName":"Tyrosine Kinase Inhibitor","longName":"5127433","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB7E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB11FDFC-C468-43B9-E053-4EBD850A3C74","beginDate":"2022-03-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-03-25","modifiedBy":"ONEDATA","dateModified":"2022-03-25","deletedIndicator":"No"},{"value":"Topotecan 1.25 mg/m2 IV","valueDescription":"Topotecan 1.25 mg/m2 IV","ValueMeaning":{"publicId":"8137777","version":"1","preferredName":"Topotecan 1.25 mg/m2 IV","longName":"8137777","preferredDefinition":"Topotecan 1.25 mg/m2 IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD8DD73-074C-2EA3-E053-4EBD850A781D","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD8DD73-0765-2EA3-E053-4EBD850A781D","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"Topotecan 4 mg/m2 IV","valueDescription":"Topotecan 4 mg/m2 IV","ValueMeaning":{"publicId":"8137778","version":"1","preferredName":"Topotecan 4 mg/m2 IV","longName":"8137778","preferredDefinition":"Topotecan 4 mg/m2 IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD8DD73-076F-2EA3-E053-4EBD850A781D","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD8DD73-0788-2EA3-E053-4EBD850A781D","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"Pegylated liposomal doxorubicin 40 mg/m2 IV","valueDescription":"Pegylated liposomal doxorubicin 40 mg/m2 IV","ValueMeaning":{"publicId":"8137779","version":"1","preferredName":"Pegylated liposomal doxorubicin 40 mg/m2 IV","longName":"8137779","preferredDefinition":"Pegylated liposomal doxorubicin 40 mg/m2 IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD8DD73-0792-2EA3-E053-4EBD850A781D","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD8DD73-07AB-2EA3-E053-4EBD850A781D","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"Paclitaxel 80 mg/m2 IV","valueDescription":"Paclitaxel 80 mg/m2 IV","ValueMeaning":{"publicId":"8137780","version":"1","preferredName":"Paclitaxel 80 mg/m2 IV","longName":"8137780","preferredDefinition":"Paclitaxel 80 mg/m2 IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD8DD73-07B5-2EA3-E053-4EBD850A781D","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD8DD73-07CE-2EA3-E053-4EBD850A781D","beginDate":"2022-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"3 Drug Reinduction","valueDescription":null,"ValueMeaning":{"publicId":"13230826","version":"1","preferredName":"3 Drug Reinduction","longName":"13230826v1.00","preferredDefinition":"3 Drug Reinduction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F780BC37-4E5C-3389-E053-731AD00ACDAE","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F780BC37-4E5E-3389-E053-731AD00ACDAE","beginDate":"2023-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","deletedIndicator":"No"},{"value":"FLA","valueDescription":null,"ValueMeaning":{"publicId":"13230827","version":"1","preferredName":"FLA","longName":"13230827v1.00","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F780BC37-4E5D-3389-E053-731AD00ACDAE","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F780BC37-4E5F-3389-E053-731AD00ACDAE","beginDate":"2023-03-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","deletedIndicator":"No"},{"value":"FLOT","valueDescription":null,"ValueMeaning":{"publicId":"13456564","version":"1","preferredName":"FLOT Regimen","longName":"13456564v1.00","preferredDefinition":"A regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel that can be used in the treatment of gastric, esophageal and esophagogastric junction cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLOT Regimen","conceptCode":"C160565","definition":"A regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel that can be used in the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA5252CC-0E13-77A9-E053-731AD00A46C2","latestVersionIndicator":"Yes","beginDate":"2023-04-27","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-27","modifiedBy":"GDEEN","dateModified":"2023-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA5252CC-0E15-77A9-E053-731AD00A46C2","beginDate":"2023-04-27","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-27","modifiedBy":"FINCHAMB","dateModified":"2023-04-27","deletedIndicator":"No"},{"value":"CAPOX/mFOLFOX","valueDescription":null,"ValueMeaning":{"publicId":"13456565","version":"1","preferredName":"CAPOX Regimen Modified FOLFOX Regimen","longName":"13456565v1.00","preferredDefinition":"A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers._A modified version of the FOLFOX regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin that may be used in the treatment of colorectal cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAPOX Regimen","conceptCode":"C63596","definition":"A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Modified FOLFOX Regimen","conceptCode":"C198948","definition":"A modified version of the FOLFOX regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin that may be used in the treatment of colorectal cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA5252CC-0E14-77A9-E053-731AD00A46C2","latestVersionIndicator":"Yes","beginDate":"2023-04-27","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-27","modifiedBy":"FINCHAMB","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA5252CC-0E16-77A9-E053-731AD00A46C2","beginDate":"2023-04-27","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-27","modifiedBy":"FINCHAMB","dateModified":"2023-04-27","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":null,"ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B17C48-C9E3-6B18-E063-731AD00A5359","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"Azacitidine","valueDescription":null,"ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B17C48-C9E4-6B18-E063-731AD00A5359","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"ChemoRT + Capecitabine","valueDescription":null,"ValueMeaning":{"publicId":"14616453","version":"1","preferredName":"Chemoradiotherapy and Capecitabine","longName":"14616453v1.00","preferredDefinition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. _An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AACDF1A-4BA9-3D28-E063-731AD00A0577","latestVersionIndicator":"Yes","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0AACDF1A-4BAA-3D28-E063-731AD00A0577","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","deletedIndicator":"No"},{"value":"ChemoRT + 5-Fluorouracil","valueDescription":null,"ValueMeaning":{"publicId":"14616455","version":"1","preferredName":"Chemoradiotherapy And Fluorouracil","longName":"14616455v1.00","preferredDefinition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. _An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AACFF4F-E0EA-427A-E063-731AD00AE4AA","latestVersionIndicator":"Yes","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0AACFF4F-E0ED-427A-E063-731AD00AE4AA","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","deletedIndicator":"No"},{"value":"5FU IV Bolus","valueDescription":null,"ValueMeaning":{"publicId":"14616456","version":"1","preferredName":"Fluorouracil Intravenous Bolus","longName":"14616456v1.00","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions._A volume of drug intended to be administered into a vein at a relatively fast rate. The volume of drug and the rate of administration are specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intravenous Bolus","conceptCode":"C38274","definition":"A volume of drug intended to be administered into a vein at a relatively fast rate. The volume of drug and the rate of administration are specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AACFF4F-E0EB-427A-E063-731AD00AE4AA","latestVersionIndicator":"Yes","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0AACFF4F-E0EE-427A-E063-731AD00AE4AA","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","deletedIndicator":"No"},{"value":"5FU Infusion Procedure","valueDescription":null,"ValueMeaning":{"publicId":"14616457","version":"1","preferredName":"Fluorouracil Infusion Procedure","longName":"14616457v1.00","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions._Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infusion Procedure","conceptCode":"C15388","definition":"Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AACFF4F-E0EC-427A-E063-731AD00AE4AA","latestVersionIndicator":"Yes","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0AACFF4F-E0EF-427A-E063-731AD00AE4AA","beginDate":"2023-11-21","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-21","modifiedBy":"CLOHNES","dateModified":"2023-11-21","deletedIndicator":"No"},{"value":"AMG330","valueDescription":null,"ValueMeaning":{"publicId":"13956334","version":"1","preferredName":"Eluvixtamab","longName":"13956334v1.00","preferredDefinition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eluvixtamab","conceptCode":"C123332","definition":"A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE3ECDC8-A04A-593E-E053-731AD00A53F1","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3441-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Arsenic Trioxide","valueDescription":null,"ValueMeaning":{"publicId":"3377438","version":"1","preferredName":"Arsenic Trioxide","longName":"3377438","preferredDefinition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic Trioxide","conceptCode":"C1005","definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0B0-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3442-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"ATRA","valueDescription":null,"ValueMeaning":{"publicId":"5342173","version":"1","preferredName":"Tretinoin","longName":"5342173","preferredDefinition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-3A61-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3443-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Bosutinib","valueDescription":null,"ValueMeaning":{"publicId":"3379565","version":"1","preferredName":"Bosutinib","longName":"3379565","preferredDefinition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bosutinib","conceptCode":"C60809","definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-371C-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3444-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Cladribine","valueDescription":null,"ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3445-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Crenolanib","valueDescription":null,"ValueMeaning":{"publicId":"3422120","version":"1","preferredName":"Crenolanib","longName":"3422120","preferredDefinition":"An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. PDGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crenolanib","conceptCode":"C64639","definition":"An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3413-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3446-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":null,"ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3447-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Decitabine","valueDescription":null,"ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3448-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Enasidenib","valueDescription":null,"ValueMeaning":{"publicId":"6429528","version":"1","preferredName":"Enasidenib","longName":"6429528","preferredDefinition":"An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enasidenib","conceptCode":"C111573","definition":"An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AEF0CD-D75A-3B8E-E053-F662850AA3C4","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3449-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Flotetuzumab","valueDescription":null,"ValueMeaning":{"publicId":"13636989","version":"1","preferredName":"Flotetuzumab","longName":"13636989v1.00","preferredDefinition":"An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flotetuzumab","conceptCode":"C117238","definition":"An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC72D408-1E2E-7022-E053-731AD00A12C4","latestVersionIndicator":"Yes","beginDate":"2023-05-24","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-24","modifiedBy":"DWARZEL","dateModified":"2023-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344A-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":null,"ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344B-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Gilteritinib","valueDescription":null,"ValueMeaning":{"publicId":"6429350","version":"1","preferredName":"Gilteritinib","longName":"6429350","preferredDefinition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gilteritinib","conceptCode":"C116722","definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D70B-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344C-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":null,"ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344D-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"IMGN632","valueDescription":null,"ValueMeaning":{"publicId":"13956327","version":"1","preferredName":"Pivekimab Sunirine","longName":"13956327v1.00","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pivekimab Sunirine","conceptCode":"C184834","definition":"An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE3EC8E1-C64C-58A4-E053-731AD00A33F8","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344E-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Janssen Menin Inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"14648431","version":"1","preferredName":"Menin-MLL Interaction Inhibitor JNJ-75276617","longName":"14648431v1.00","preferredDefinition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor JNJ-75276617 inhibits the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of leukemic cells with either KMT2A alterations such as gene rearrangements (KMT2A-r), duplications, and amplification, or nucleophosmin 1 gene (NPM1) alterations. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Menin-MLL Interaction Inhibitor JNJ-75276617","conceptCode":"C179561","definition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor JNJ-75276617 inhibits the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of leukemic cells with either KMT2A alterations such as gene rearrangements (KMT2A-r), duplications, and amplification, or nucleophosmin 1 gene (NPM1) alterations. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BD973DC-343F-5CA2-E063-731AD00AECED","latestVersionIndicator":"Yes","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-344F-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Midostaurin","valueDescription":null,"ValueMeaning":{"publicId":"5805895","version":"1","preferredName":"Midostaurin","longName":"5805895","preferredDefinition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midostaurin","conceptCode":"C1872","definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4464-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"COOPERM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3450-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Quizartinib","valueDescription":null,"ValueMeaning":{"publicId":"6429348","version":"1","preferredName":"Quizartinib","longName":"6429348","preferredDefinition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quizartinib","conceptCode":"C68936","definition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D6C5-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3451-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"SNDX-5613 (Menin inh)","valueDescription":null,"ValueMeaning":{"publicId":"13961784","version":"1","preferredName":"Revumenib","longName":"13961784v1.00","preferredDefinition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Revumenib","conceptCode":"C165776","definition":"An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE46F21C-4B81-46AA-E053-731AD00ACC44","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3452-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":null,"ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3453-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"STRO-001","valueDescription":null,"ValueMeaning":{"publicId":"13596807","version":"1","preferredName":"Anti-CD74 Antibody-drug Conjugate STRO-001","longName":"13596807v1.00","preferredDefinition":"An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD74 Antibody-drug Conjugate STRO-001","conceptCode":"C148066","definition":"An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC056E4B-FC3D-6FBC-E053-731AD00A289A","latestVersionIndicator":"Yes","beginDate":"2023-05-19","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-19","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3454-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"STRO-002","valueDescription":null,"ValueMeaning":{"publicId":"13956356","version":"1","preferredName":"Luveltamab Tazevibulin","longName":"13956356v1.00","preferredDefinition":"An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luveltamab Tazevibulin","conceptCode":"C158067","definition":"An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE3EF614-0FCC-60EF-E053-731AD00AE892","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3455-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Trametinib","valueDescription":null,"ValueMeaning":{"publicId":"3523220","version":"1","preferredName":"Trametinib","longName":"3523220","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-4590-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3456-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Uproleselan","valueDescription":null,"ValueMeaning":{"publicId":"13744255","version":"1","preferredName":"Uproleselan","longName":"13744255v1.00","preferredDefinition":"A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uproleselan","conceptCode":"C119743","definition":"A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA635B9-A67C-6684-E053-731AD00AD4B3","latestVersionIndicator":"Yes","beginDate":"2023-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-27","modifiedBy":"DWARZEL","dateModified":"2023-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3457-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"},{"value":"Ymabs huCD33xCd3 BsAb","valueDescription":null,"ValueMeaning":{"publicId":"14648432","version":"1","preferredName":"Anti-CD33/CD3 Bispecific Antibody","longName":"14648432v1.00","preferredDefinition":"A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD33/CD3 bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and CD33 on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-CD33/CD3 Bispecific Antibody","conceptCode":"C188201","definition":"A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD33/CD3 bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and CD33 on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BD973DC-3440-5CA2-E063-731AD00AECED","latestVersionIndicator":"Yes","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BD973DC-3458-5CA2-E063-731AD00AECED","beginDate":"2023-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEA670A9-0FB6-0537-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-05-27","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":"2023.12.6 PVs added per ticket request CADSR0003157. ak 11/21/23 4 PVs added for CCTG ticket number CADSR0003101 cjl; 2023.9.6 PVs added per ticket request CADSR0002816. ak 2023.3.22 PVs added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"If Chemotherapy, type of chemotherapy received:","url":null,"context":"COG"},{"name":"Type of chemotherapy received:","type":"Preferred Question Text","description":"Type of chemotherapy received:","url":null,"context":"COG"},{"name":"COG CRF TEXT 2","type":"Alternate Question Text","description":"Therapy type:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8488B7A1-8170-02B0-E053-F662850AFAA0","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-20","modifiedBy":"LEEW","dateModified":"2022-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}